Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 2/20 | 0.39 |
| ▸ | DDO | Q99489 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4281644 | 0.73 | IMPDH2 (0.41) | CYP1A2ALDH1A1DAODDOCA1 | |
| SCHEMBL4276905 | 0.73 | CYP1A2 (0.46) | CYP1A2CYP2A6DAOGPR84TSHR | |
| SCHEMBL442418 | 0.73 | DAO (0.39) | DAODDOGPR84 | |
| SCHEMBL1243755 | 0.72 | KIF11 (0.46) | ALDH1A1KIF11CA2TSHR | |
| SCHEMBL9740669 | 0.72 | GAA (0.39) | CYP1A2ALDH1A1ATMCA2TSHR | |
| SCHEMBL1539240 | 0.72 | ABCG2 (0.41) | CYP2A6ALDH1A1ATMCA1CA2 | |
| SCHEMBL9740801 | 0.69 | MEN1 (0.47) | CYP1A2DAOCYP2C19 | |
| SCHEMBL20562764 | 0.68 | NR4A1 (0.48) | ALDH1A1CA1CA2CA7CA9 | |
| SCHEMBL9739950 | 0.68 | IMPDH2 (0.41) | ALDH1A1CA1CA2TSHR | |
| SCHEMBL4693055 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1208 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697812-B2 | Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2023-07-11 | — | — | US | claimed |
| US-11359198-B2 | Extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2022-06-14 | — | — | US | claimed |
| US-20210292757-A1 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | NOVO NORDISK A/S (DK) | 2021-09-23 | — | — | US | claimed |
| EP-3865576-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | Dicerna Pharmaceuticals, Inc. (US) | 2021-08-18 | — | — | EP | claimed |
| US-10870849-B2 | Extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2020-12-22 | — | — | US | claimed |
| US-10837013-B2 | Extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2020-11-17 | — | — | US | claimed |
| US-20200031862-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | DICERNA PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | claimed |
| EP-3234132-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | Dicerna Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | claimed |
| WO-2016100401-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | DICERNA PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | claimed |
| US-20150038555-A1 | Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression | NOVO NORDISK A/S (DK) | 2015-02-05 | — | — | US | claimed |
| US-20150038554-A1 | Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression | NOVO NORDISK A/S (DK) | 2015-02-05 | — | — | US | claimed |
| WO-2013071079-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-05-16 | — | — | WO | claimed |
| US-20130041010-A1 | COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DSRNA CONTAINING MODIFIED NUCLEOTIDES | DICERNA PHARMACEUTICALS, INC. (US) | 2013-02-14 | — | — | US | claimed |
| US-20110288147-A1 | Compositions and methods for the specific inhibition of gene expression by DSRNA containing a tetraloop | DICERNA PHARMACEUTICALS, INC. | 2011-11-24 | — | — | US | claimed |
| EP-2341943-A2 | COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DSRNA POSSESSING MODIFICATIONS | Dicerna Pharmaceuticals, Inc. (US) | 2011-07-13 | — | — | EP | claimed |
| US-20100331389-A1 | Compositions and methods for the specific inhibition of gene expression by dsRNA containing modified nucleotides | DICERNA PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | claimed |
| WO-2010033225-A2 | COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DSRNA POSSESSING MODIFICATIONS | DICERNA PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | WO | claimed |
| EP-1828215-A2 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | Alnylam Pharmaceuticals Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006093526-A2 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | claimed |
| US-20240238210-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ARES CAPITAL CORPORATION, AS AGENT | 2024-07-18 | — | — | US | disclosed |
| WO-2024151673-A2 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151685-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| WO-2024151687-A1 | GENETIC SWITCHES AND THEIR USE IN TREATING CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20240238473-A1 | RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-07-18 | — | — | US | disclosed |
| US-20240229037-A1 | SIRNA TARGETING 17Beta-HYDROXYSTEROID DEHYDROGENASE TYPE 13 AND SIRNA CONJUGATE | TUOJIE BIOTECH (SHANGHAI) CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| EP-4392140-A1 | IN VITRO TRANSCRIPTION TECHNOLOGIES | BioNTech SE (DE) | 2024-07-03 | — | — | EP | disclosed |
| WO-2024133160-A1 | HEPATITIS B COMPOSITIONS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-06-27 | — | — | WO | disclosed |
| US-20240209068-A1 | MUCOSAL EXPRESSION OF ANTIBODY STRUCTURES AND ISOTYPES BY MRNA | MODERNATX, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4387596-A1 | LOW-DOSE LYOPHILIZED RNA VACCINES AND METHODS FOR PREPARING AND USING THE SAME | GlaxoSmithKline Biologicals SA (BE) | 2024-06-26 | — | — | EP | disclosed |
| EP-4387597-A1 | FREEZE-DRYING OF LIPID NANOPARTICLES (LNPS) ENCAPSULATING RNA AND FORMULATIONS THEREOF | GlaxoSmithKline Biologicals SA (BE) | 2024-06-26 | — | — | EP | disclosed |
| US-12018260-B2 | Tunable Reversir™ compounds | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240200061-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | ALNYLAM PHARMACEUTICALS, INC. | 2024-06-20 | — | — | US | disclosed |
| WO-2024123993-A1 | SELECTIVE APOPTOSIS-INDUCING METHODS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-06-13 | — | — | WO | disclosed |
| EP-4380576-A2 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | Verve Therapeutics, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| US-12005074-B2 | Extrahepatic delivery | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| WO-2024113009-A1 | AGENTS, COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY | THE UNIVERSITY OF QUEENSLAND (AU) | 2024-06-06 | — | — | WO | disclosed |
| US-20240173400-A1 | HERPES SIMPLEX VIRUS VACCINE | MODERNATX, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| US-20240174732-A1 | NUCLEIC ACID MOLECULES ENCODING TRIF AND ADDITIONAL POLYPEPTIDES AND THEIR USE IN TREATING CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2024-05-30 | — | — | US | disclosed |
| US-20240175020-A1 | COMPOSITIONS OF MODIFIED TREMS AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2024-05-30 | — | — | US | disclosed |
| US-20240175028-A1 | DOSING OF siRNA COMPOUNDS TO THE CISTERNA MAGNA | ALNYLAM PHARMACEUTICALS, INC (US) | 2024-05-30 | — | — | US | disclosed |
| EP-4373937-A1 | METABOLIC DISORDER-ASSOCIATED TARGET GENE IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| CN-118076360-A | Compositions and methods for targeted RNA delivery | 维乎医疗有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4370132-A2 | MULTIPLEXING TARGETING LIGANDS THROUGH CLICK CHEMISTRY AT THE ANOMERIC SITE OF SUGARS | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-4370136-A2 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240156952-A1 | HERPES SIMPLEX VIRUS VACCINE | MODERNATX, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4367237-A2 | BIS-RNAI COMPOUNDS FOR CNS DELIVERY | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-4367134-A1 | UTILIZATION OF ANTIBODIES TO SHAPE ANTIBODY RESPONSES TO AN ANTIGEN | Regeneron Pharmaceuticals, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-4367125-A1 | AMINOOXY CLICK CHEMISTRY (AOCC): A VERSATILE BIOCONJUGATION APPROACH | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| WO-2024089633-A1 | RNA MOLECULES ENCODING RSV-F AND VACCINES CONTAINING THEM | PFIZER INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024084089-A1 | METHODS AND USES ASSOCIATED WITH LIQUID COMPOSITIONS | BioNTech SE (DE) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024083345-A1 | METHODS AND USES ASSOCIATED WITH LIQUID COMPOSITIONS | BioNTech SE (DE) | 2024-04-25 | — | — | WO | disclosed |
| US-20240131166-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. | 2024-04-25 | — | — | US | disclosed |
| WO-2024077191-A1 | NUCLEIC ACID MOLECULES ENCODING TRIF AND ADDITIONALPOLYPEPTIDES AND THEIR USE IN TREATING CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20240116973-A1 | MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| EP-4349404-A2 | RESPIRATORY VIRUS VACCINES | ModernaTX, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4349405-A2 | RESPIRATORY VIRUS VACCINES | ModernaTX, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2024073732-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20240110214-A1 | RNA MANUFACTURING | BioNTech SE (DE) | 2024-04-04 | — | — | US | disclosed |
| WO-2024073709-A2 | MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024064965-A2 | NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF | ADVANCED RNA VACCINE (ARV) TECHNOLOGIES, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| US-20240100169-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. | 2024-03-28 | — | — | US | disclosed |
| US-20240100152-A1 | MODIFIED POLYNUCLEOTIDES ENCODING THE SARS-COV-2 SPIKE PROTEIN FOR SAFER DESIGNS OF CORONAVIRUS VACCINES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2024-03-28 | — | — | US | disclosed |
| WO-2023283434-A9 | AMINOOXY CLICK CHEMISTRY (AOCC): A VERSATILE BIOCONJUGATION APPROACH | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| US-20240100145-A1 | VLP ENTEROVIRAL VACCINES | Moderna TX, Inc. (US) | 2024-03-28 | — | — | US | disclosed |
| CN-111849912-B | Method for activating T cells using inducible chimeric polypeptides | 贝里坤制药股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| US-20240082378-A1 | Staphylococcus aureus Antigen-Based Nucleic Acid Vaccines | UNIVERSITY OF ROCHESTER | 2024-03-14 | — | — | US | disclosed |
| EP-3914734-B1 | COMPOSITIONS AND METHOD FOR SYNTHESIZING NUCLEIC ACIDS | HARVARD COLLEGE (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-3458107-B1 | POLYNUCLEOTIDES ENCODING JAGGED1 FOR THE TREATMENT OF ALAGILLE SYNDROME | MODERNATX INC (US) | 2024-03-13 | — | — | EP | disclosed |
| US-11918644-B2 | Varicella zoster virus (VZV) vaccine | MODERNATX, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| WO-2024041772-A1 | RSV-F PROTEINS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024041773-A1 | RSV-F PROTEINS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2024-02-29 | — | — | WO | disclosed |
| EP-4328310-A1 | SIRNA TARGETING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 AND SIRNA CONJUGATE | Tuojie Biotech (Shanghai) Co., Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-11912996-B2 | Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2024039776-A2 | UNIVERSAL NON-TARGETING SIRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| EP-4313109-A1 | THANOTRANSMISSION POLYPEPTIDES AND THEIR USE IN TREATING CANCER | Flagship Pioneering Innovations V, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-3460064-B1 | EFFICIENT PROTEIN EXPRESSION IN VIVO USING MODIFIED RNA (MOD-RNA) | THE GENERAL HOSPITAL CORP D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-4314046-A1 | MUCOSAL EXPRESSION OF ANTIBODY STRUCTURES AND ISOTYPES BY MRNA | ModernaTX, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20240024422-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-01-25 | — | — | US | disclosed |
| US-20240024505-A1 | SYNTHETIC CELLULAR SIGNALING PATHWAYS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-01-25 | — | — | US | disclosed |
| WO-2024015890-A1 | NOROVIRUS MRNA VACCINES | MODERNATX, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20240018177-A1 | UTILITY OF NEMATODE SMALL MOLECULES | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH | 2024-01-18 | — | — | US | disclosed |
| WO-2024015428-A1 | SYNTHETIC CELLULAR SIGNALING PATHWAYS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-3458105-B1 | POLYNUCLEOTIDES ENCODING GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE FOR THE TREATMENT OF GALACTOSEMIA TYPE 1 | MODERNATX INC (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-117402829-A | Dual control for therapeutic cell activation or elimination | 贝里坤制药股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| US-11873493-B2 | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872278-B2 | Combination HMPV/RSV RNA vaccines | MODERNATX, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873327-B2 | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof | MODERNATX, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20240009225-A1 | EXTRAHEPATIC DELIVERY | BANK OF AMERICA, N.A. | 2024-01-11 | — | — | US | disclosed |
| EP-4301858-A1 | DOSING OF SIRNA COMPOUNDS TO THE CISTERNA MAGNA | Alnylam Pharmaceuticals, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| EP-4301405-A1 | VLP ENTEROVIRAL VACCINES | ModernaTX, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| US-11866700-B2 | Liposomal spherical nucleic acid (SNA) constructs presenting antisense oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor mRNA | EXICURE OPERATING COMPANY (US) | 2024-01-09 | — | — | US | disclosed |
| US-11866754-B2 | Trinucleotide mRNA cap analogs | MODERNATX, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| WO-2024006999-A2 | CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2024006953-A2 | MONOMERS AND METHODS FOR SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-11851658-B2 | Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| US-11849688-B2 | Compositions and methods for modulating immunity in plants | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| WO-2023242817-A2 | RECOMBINANT RNA MOLECULES COMPRISING UNTRANSLATED REGIONS OR SEGMENTS ENCODING SPIKE PROTEIN FROM THE OMICRON STRAIN OF SEVERE ACUTE RESPIRATORY CORONAVIRUS-2 | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-12-21 | — | — | WO | disclosed |
| CN-117241837-A | Hepatitis b virus siRNA and siRNA conjugates | 上海拓界生物医药科技有限公司 | 2023-12-15 | — | — | CN | disclosed |
| US-11839647-B2 | Methods for inducing partial apoptosis using caspase polypeptides | BELLICUM PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230390379-A1 | RESPIRATORY SYNCYTIAL VIRUS VACCINE | MODERNATX, INC. (US) | 2023-12-07 | — | — | US | disclosed |
| EP-4286517-A2 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/CAS SYSTEMS | President and Fellows of Harvard College (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-4281085-A1 | MODIFIED DOUBLE STRANDED OLIGONUCLEOTIDES | Alnylam Pharmaceuticals, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| US-20230374079-A1 | NUCLEIC ACID VACCINES FOR VARICELLA ZOSTER VIRUS (VZV) | MODERNATX, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| EP-4277636-A1 | MODIFIED OLIGONUCLEOTIDES | Alnylam Pharmaceuticals, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-4277651-A1 | <SMALLCAPS/>? ? ?STAPHYLOCOCCUS? ? ? ? ?AUREUS ANTIGEN-BASED NUCLEIC ACID VACCINES | University of Rochester (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230364083-A1 | HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA | ACETYLON PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023220744-A2 | SINGLE-STRANDED LOOP OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230359371-A1 | METHODS OF USING OX40 LIGAND ENCODING POLYNUCLEOTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2023-11-09 | — | — | US | disclosed |
| EP-4271696-A2 | CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS | Alnylam Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-4271695-A2 | 2'-MODIFIED NUCLEOSIDE BASED OLIGONUCLEOTIDE PRODRUGS | Alnylam Pharmaceuticals, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230346907-A1 | SEXUALLY TRANSMITTED DISEASE VACCINES | MODERNATX, INC. (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230346928-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | ARES CAPITAL CORPORATION, AS AGENT | 2023-11-02 | — | — | US | disclosed |
| EP-4269601-A2 | MODIFIED T CELLS AND METHODS OF MAKING AND USING THE SAME | President and Fellows of Harvard College (US) | 2023-11-01 | — | — | EP | disclosed |
| US-11801227-B2 | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis | MODERNATX, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11801306-B2 | Compositions and methods for targeted RNA delivery | VERVE THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230340488-A1 | TREATMENT OF SKIN DISEASES AND DISORDERS USING INHIBITORS OF KALLIKREIN-RELATED PEPTIDASES (KLK) | EXICURE OPERATING COMPANY (US) | 2023-10-26 | — | — | US | disclosed |
| CN-116940681-A | siRNA and siRNA conjugates targeting 17 beta-hydroxysteroid dehydrogenase type 13 | 上海拓界生物医药科技有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20230330260-A1 | RNA FORMULATIONS | ModemaTX, Inc. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230331763-A1 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | VERVE THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| EP-4259161-A1 | RNA MANUFACTURING | BioNTech SE (DE) | 2023-10-18 | — | — | EP | disclosed |
| US-11786607-B2 | RNA formulations | MODERNATX, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230323371-A1 | POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | MODERNATX, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230310576-A1 | BROAD SPECTRUM INFLUENZA VIRUS VACCINE | MODERNATX, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-11773390-B2 | Methods and compositions for the specific inhibition of Complement Component 5(C5) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| CN-116829567-A | Oligonucleotide prodrugs based on cyclic disulfide modified phosphates | 阿尔尼拉姆医药品有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230304002-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | BANK OF AMERICA, N.A. | 2023-09-28 | — | — | US | disclosed |
| US-20230303632-A1 | NUCLEIC ACID VACCINES FOR VARICELLA ZOSTER VIRUS (VZV) | MODERNATX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2023177866-A1 | DECARBOXYLATIVE ACETOXYLATION USING MN(II) OR MN(III) REAGENT FOR SYNTHESIS OF 4'-ACETOXY- NUCLEOSIDE AND USE THEREOF FOR SYNTHESIS OF CORRESPONDING 4'-(DIMETHOXYPHOSPHORYL)METHOXY- NUCLEOTIDE | DICERNA PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230287418-A1 | MODIFIED SIRNA WITH REDUCED OFF-TARGET ACTIVITY | TUOJIE BIOTECH(SHANGHAI) CO., LTD. (CN) | 2023-09-14 | — | — | US | disclosed |
| US-20230285538-A1 | EFFICACIOUS MRNA VACCINES | MODERNATX, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-11752206-B2 | Herpes simplex virus vaccine | MODERNATX, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230277675-A1 | SYSTEMIC DELIVERY OF OLIGONUCLEOTIDES | NOVO NORDISK A/S (DK) | 2023-09-07 | — | — | US | disclosed |
| WO-2023167880-A2 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | VERVE THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2022187617-A9 | DOSING OF SIRNA COMPOUNDS TO THE CISTERNA MAGNA | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20230270685-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | MODERNATX, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| US-20230270831-A1 | METHODS FOR INDUCING SELECTIVE APOPTOSIS | BAYLOR COLLEGE OF MEDICINE | 2023-08-31 | — | — | US | disclosed |
| CN-116615542-A | Systemic delivery of oligonucleotides | 迪克纳制药公司 | 2023-08-18 | — | — | CN | disclosed |
| US-20230257745-A1 | Circular siRNAs | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | disclosed |
| US-20230242569-A1 | PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE | 2023-08-03 | — | — | US | disclosed |
| EP-4218805-A1 | INFECTIOUS DISEASE VACCINES | ModernaTX, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4219544-A1 | T-CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF | Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum (NL) | 2023-08-02 | — | — | EP | disclosed |
| US-20230233608-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| EP-3273976-B1 | MODIFIED T CELLS AND METHODS OF MAKING AND USING THE SAME | HARVARD COLLEGE (US) | 2023-07-26 | — | — | EP | disclosed |
| EP-4208549-A1 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | Verve Therapeutics, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| US-11697812-B2 | Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-11696954-B2 | Synthesis of spherical nucleic acids using lipophilic moieties | EXICURE OPERATING COMPANY (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230212204-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | THE SCRIPPS RESEARCH INSTITUTE | 2023-07-06 | — | — | US | disclosed |
| EP-2981617-B1 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/CAS SYSTEMS | HARVARD COLLEGE (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116368226-A | Compositions and methods for capping RNA | 维乎医疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230203509-A1 | TREM COMPOSITIONS AND METHODS RELATING THERETO | FLAGSHIP PIONEERING INNOVATIONS VI LLC (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203510-A1 | TREM COMPOSITIONS AND METHODS RELATING THERETO | FLAGSHIP PIONEERING INNOVATIONS VI LLC (US) | 2023-06-29 | — | — | US | disclosed |
| EP-4201955-A1 | T-CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF | Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum (NL) | 2023-06-28 | — | — | EP | disclosed |
| US-11687256-B2 | Methods of using OX40 ligand encoding polynucleotides | MODERNATX, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20230183769-A1 | IN VITRO TRANSCRIPTION TECHNOLOGIES | BioNTech SE (DE) | 2023-06-15 | — | — | US | disclosed |
| EP-4192505-A1 | SYSTEMIC DELIVERY OF OLIGONUCLEOTIDES | Dicerna Pharmaceuticals, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-4192477-A1 | TREATMENT OF SKIN DISEASES AND DISORDERS USING INHIBITORS OF KALLIKREIN-RELATED PEPTIDASES (KLK) | Exicure Operating Company (US) | 2023-06-14 | — | — | EP | disclosed |
| EP-4194553-A1 | MODIFIED SIRNA WITH REDUCED OFF-TARGET ACTIVITY | Tuojie Biotech (Shanghai) Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| US-11673908-B2 | Utility of nematode small molecules | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-06-13 | — | — | US | disclosed |
| US-11667918-B2 | Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| EP-4186518-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | ModernaTX, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-11660341-B2 | mRNA combination therapy for the treatment of cancer | MODERNATX, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11649461-B2 | Polynucleotides encoding α-galactosidase A for the treatment of Fabry disease | MODERNATX, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11643441-B1 | Nucleic acid vaccines for varicella zoster virus (VZV) | MODERNATX, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| WO-2023069495-A1 | OLIGONUCLEOTIDES WITH 2'-DEOXY-2'-F-2'-C-METHYL NUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20230132377-A9 | OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES | ALPHA ANOMERIC SAS (FR) | 2023-04-27 | — | — | US | disclosed |
| US-11634713-B2 | Extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230123981-A1 | 4'-O-METHYLENE PHOSPHONATE NUCLEIC ACIDS AND ANALOGUES THEREOF | NOVO NORDISK A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| WO-2023064530-A1 | EXTRA-HEPATIC DELIVERY IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| US-20230116376-A1 | HUMAN CYTOMEGALOVIRUS RNA VACCINES | MODERNATX, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230116843-A1 | POLYNUCLEOTIDES ENCODING TETHERED INTERLEUKIN-12 (IL12) POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2023-04-13 | — | — | US | disclosed |
| US-20230114180-A1 | RESPIRATORY SYNCYTIAL VIRUS VACCINE | MODERNATX, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230112986-A1 | POLYNUCLEOTIDES ENCODING PORPHOBILINOGEN DEAMINASE FOR THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA | MODERNATX, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230111150-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF KRAS BY ASYMMETRIC DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. | 2023-04-13 | — | — | US | disclosed |
| CN-115955973-A | Modified siRNA with reduced off-target activity | 上海拓界生物医药科技有限公司 | 2023-04-11 | — | — | CN | disclosed |
| WO-2023015223-A9 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| EP-4159741-A1 | METHOD FOR PRODUCING A CHIMERIC POLYNUCLEOTIDE ENCODING A POLYPEPTIDE HAVING A TRIAZOLE-CONTAINING INTERNUCLEOTIDE LINKAGE | ModernaTX, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-11613554-B2 | Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-03-28 | — | — | US | disclosed |
| WO-2023044346-A2 | VACCINES FOR CORONAVIRUS PREVENTION AND TREATMENT | AUSPER BIOPHARMA CO., LTD. (CN) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023042099-A2 | VACCINES FOR CORONAVIRUS PREVENTION AND TREATMENT | AUSPER BIOPHARMA CO., LTD. (CN) | 2023-03-23 | — | — | WO | disclosed |
| WO-2022155418-A9 | MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-03-09 | — | — | WO | disclosed |
| US-11596609-B2 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | MODERNATX, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-11597929-B2 | Extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20230069235-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA | NOVO NORDISK A/S (DK) | 2023-03-02 | — | — | US | disclosed |
| WO-2023025404-A1 | IN VITRO TRANSCRIPTION TECHNOLOGIES | BioNTech SE (DE) | 2023-03-02 | — | — | WO | disclosed |
| US-20230065562-A1 | DUAL CONTROLS FOR THERAPEUTIC CELL ACTIVATION OR ELIMINATION | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-03-02 | — | — | US | disclosed |
| US-20230054178-A1 | TREM COMPOSITIONS AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2023-02-23 | — | — | US | disclosed |
| US-20230058834-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF TRANSTHYRETIN (TTR) BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| WO-2023021427-A1 | FREEZE-DRYING OF LIPID NANOPARTICLES (LNPS) ENCAPSULATING RNA AND FORMULATIONS THEREOF | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023021421-A1 | LOW-DOSE LYOPHILIZED RNA VACCINES AND METHODS FOR PREPARING AND USING THE SAME | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2023-02-23 | — | — | WO | disclosed |
| EP-4137509-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | ModernaTX, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| WO-2022031433-A9 | SYSTEMIC DELIVERY OF OLIGONUCLEOTIDES | DICERNA PHARMACEUTICALS, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| US-11576961-B2 | Broad spectrum influenza virus vaccine | MODERNATX, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20230044692-A1 | HUMAN CYTOMEGALOVIRUS VACCINE | MODERNATX, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| WO-2023015223-A2 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-20230041964-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | MODERNATX, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11571463-B2 | Polynucleotides encoding interleukin-12 (IL12) and uses thereof | MODERNATX, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| EP-4124657-A2 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF KRAS BY ASYMMETRIC DOUBLE-STRANDED RNA | Dicerna Pharmaceuticals, Inc. (US) | 2023-02-01 | — | — | EP | disclosed |
| US-20230029257-A1 | COMPOSITIONS AND METHODS FOR LIGHT-DIRECTED BIOMOLECULAR BARCODING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230026381-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2023-01-26 | — | — | US | disclosed |
| US-20230024046-A1 | UTILITY OF NEMATODE SMALL MOLECULES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-01-26 | — | — | US | disclosed |
| US-20230029227-A1 | TUNABLE REVERSIR TM COMPOUNDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2023003922-A1 | METABOLIC DISORDER-ASSOCIATED TARGET GENE IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| US-20230015276-A1 | METHODS AND COMPOSITIONS TO INCREASE SOMATIC CELL NUCLEAR TRANSFER (SCNT) EFFICIENCY BY REMOVING HISTONE H3-LYSINE TRIMETHYLATION | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230020362-A1 | INFECTIOUS DISEASE VACCINES | MODERNATX, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230016929-A1 | EXTRAHEPATIC DELIVERY | BANK OF AMERICA, N.A. | 2023-01-19 | — | — | US | disclosed |
| WO-2023288045-A2 | SIMPLE CHEMICAL APPROACHES TO INTRODUCE 2,6-DIAMINOPURINE AND 2-AMINOADENINE CONJUGATES INTO OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023288047-A2 | MULTIPLEXING TARGETING LIGANDS THROUGH CLICK CHEMISTRY AT THE ANOMERIC SITE OF SUGARS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2023283134-A1 | UTILIZATION OF ANTIBODIES TO SHAPE ANTIBODY RESPONSES TO AN ANTIGEN | REGENERON PHARMACEUTICALS, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023283434-A1 | AMINOOXY CLICK CHEMISTRY (AOCC): A VERSATILE BIOCONJUGATION APPROACH | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| WO-2023283403-A2 | BIS-RNAI COMPOUNDS FOR CNS DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| EP-4114360-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | Verve Therapeutics, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-11541113-B2 | Human cytomegalovirus vaccine | MODERNATX, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220409720-A1 | VARICELLA ZOSTER VIRUS (VZV) VACCINE | MODERNATX, INC. (US) | 2022-12-29 | — | — | US | disclosed |
| CN-115484932-A | Compositions and methods for targeted RNA delivery | 维乎医疗有限公司 | 2022-12-16 | — | — | CN | disclosed |
| US-20220396799-A1 | THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR | DICERNA PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | disclosed |
| US-20220396793-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA | NOVO NORDISK A/S (DK) | 2022-12-15 | — | — | US | disclosed |
| EP-3084446-B1 | HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA | ACETYLON PHARMACEUTICALS INC (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220370591-A1 | COMPOSITIONS COMPRISING NUCLEIC ACIDS ENCODING STRUCTURAL TRIMERS AND METHODS OF USING THE SAME | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2022-11-24 | — | — | US | disclosed |
| CN-115298192-A | 4' -O-methylene phosphonate nucleic acids and analogs thereof | 迪克纳制药公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20220333119-A1 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2022-10-20 | — | — | US | disclosed |
| WO-2022212784-A1 | THANOTRANSMISSION POLYPEPTIDES AND THEIR USE IN TREATING CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| EP-3268014-B1 | T-CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF | ACADEMISCH ZIEKENHUIS LEIDEN H O D N LEIDS UNIV MEDISCH CENTRUM (NL) | 2022-09-21 | — | — | EP | disclosed |
| WO-2022187617-A1 | DOSING OF SIRNA COMPOUNDS TO THE CISTERNA MAGNA | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| CN-114945669-A | Extrahepatic delivery | 阿尔尼拉姆医药品有限公司 | 2022-08-26 | — | — | CN | disclosed |
| US-11421011-B2 | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof | MODERNATX, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20220257746-A1 | TROPICAL DISEASE VACCINES | MODERNATX, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| CN-114867733-A | Ligand-2' -modified nucleic acids, synthesis thereof and intermediate compounds thereof | 迪克纳制药公司 | 2022-08-05 | — | — | CN | disclosed |
| WO-2022155418-A1 | MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-07-21 | — | — | WO | disclosed |
| US-20220228149-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA | NOVO NORDISK A/S (DK) | 2022-07-21 | — | — | US | disclosed |
| WO-2022155421-A1 | STAPHYLOCOCCUS AUREUS ANTIGEN-BASED NUCLEIC ACID VACCINES | UNIVERSITY OF ROCHESTER (US) | 2022-07-21 | — | — | WO | disclosed |
| US-11390885-B2 | Methods and compositions to increase somatic cell nuclear transfer (SCNT) efficiency by removing histone H3-lysine trimethylation | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-07-19 | — | — | US | disclosed |
| WO-2022150369-A1 | COMPOUNDS FOR THE TREATMENT OF BATTEN DISEASE | EXICURE OPERATING COMPANY (US) | 2022-07-14 | — | — | WO | disclosed |
| US-11384352-B2 | RNA affinity purification | MODERNATX, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-11384356-B2 | Composition and method for oligonucleotide delivery | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-07-12 | — | — | US | disclosed |
| US-20220211743-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2022-07-07 | — | — | US | disclosed |
| WO-2022147541-A1 | COMPOUNDS FOR MODULATING SCN9A EXPRESSION | EXICURE OPERATING COMPANY (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022147214-A2 | CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022147223-A2 | 2'-MODIFIED NUCLEOSIDE BASED OLIGONUCLEOTIDE PRODRUGS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| EP-4021915-A1 | LIGAND-2'-MODIFIED NUCLEIC ACIDS, SYNTHESIS THEREOF AND INTERMEDIATE COMPOUNDS THEREOF | Dicerna Pharmaceuticals, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-3458474-B1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | MODERNATX INC (US) | 2022-07-06 | — | — | EP | disclosed |
| EP-4023249-A1 | NUCLEIC ACID VACCINES | ModernaTX, Inc. (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20220193223-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2022-06-23 | — | — | US | disclosed |
| US-11364292-B2 | CHIKV RNA vaccines | MODERNATX, INC. (US) | 2022-06-21 | — | — | US | disclosed |
| WO-2022122689-A1 | RNA MANUFACTURING | BioNTech SE (DE) | 2022-06-16 | — | — | WO | disclosed |
| EP-4011451-A1 | METAPNEUMOVIRUS MRNA VACCINES | ModernaTX, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |
| EP-4012031-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA | Dicerna Pharmaceuticals, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |
| US-11359198-B2 | Extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-11359203-B2 | Therapeutic inhibition of lactate dehydrogenase and agents therefor | DICERNA PHARMACEUTICALS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20220177885-A1 | ENDOSOMAL CLEAVABLE LINKERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| EP-3199165-B1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF KRAS BY ASYMMETRIC DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS INC (US) | 2022-06-08 | — | — | EP | disclosed |
| US-11344504-B1 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | MODERNATX, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20220162608-A1 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | NOVO NORDISK A/S (DK) | 2022-05-26 | — | — | US | disclosed |
| US-20220162565-A1 | SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC, MODIFIED RNAS AND USES THEREOF | 55 Shattuck Street (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220162554-A1 | MODIFIED T CELLS AND METHODS OF MAKING AND USING THE SAME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-05-26 | — | — | US | disclosed |
| US-20220162555-A1 | MODIFIED T CELLS AND METHODS OF MAKING AND USING THE SAME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-05-26 | — | — | US | disclosed |
| US-20220152100-A1 | METHODS FOR CONTROLLED ACTIVATION OR ELIMINATION OF THERAPEUTIC CELLS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-05-19 | — | — | US | disclosed |
| US-20220152210-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220152178-A1 | CONCATEMERIC PEPTIDE EPITOPE RNAS | MODERNATX, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220125823-A1 | EXTRAHEPATIC DELIVERY | BANK OF AMERICA, N.A. | 2022-04-28 | — | — | US | disclosed |
| US-20220125837-A1 | METHODS FOR CONTROLLED ELIMINATION OF THERAPEUTIC CELLS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-04-28 | — | — | US | disclosed |
| US-20220127604-A1 | REVERSIR TM COMPOUNDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | US | disclosed |
| EP-3718565-B1 | RESPIRATORY VIRUS VACCINES | MODERNATX INC (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11311602-B2 | Polynucleotides encoding interleukin-12 (IL12) and uses thereof | MODERNATX, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11312960-B1 | Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11312961-B1 | Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3983077-A1 | DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM | Alnylam Pharmaceuticals, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| US-20220096626-A1 | HUMAN CYTOMEGALOVIRUS VACCINE | MODERNATX, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| EP-3362461-B1 | MRNA CAP ANALOGS WITH MODIFIED PHOSPHATE LINKAGE | MODERNATX INC (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3169693-B1 | CHIMERIC POLYNUCLEOTIDES | MODERNATX INC (US) | 2022-03-09 | — | — | EP | disclosed |
| CN-107257858-B | Therapeutic inhibition of lactate dehydrogenase and reagents therefor | 戴瑟纳制药公司 | 2022-03-08 | — | — | CN | disclosed |
| US-20220056498-A1 | COMPOSITIONS AND METHOD FOR SYNTHESIZING NUCLEIC ACIDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-02-24 | — | — | US | disclosed |
| US-20220047518-A1 | PEG LIPIDS AND USES THEREOF | Moderna TX, Inc. (US) | 2022-02-17 | — | — | US | disclosed |
| US-20220031631-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | MODERNATX, INC. (US) | 2022-02-03 | — | — | US | disclosed |
| US-11235052-B2 | Chikungunya virus RNA vaccines | MODERNATX, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20220025024-A1 | METHODS FOR ACTIVATING T CELLS USING AN INDUCIBLE CHIMERIC POLYPEPTIDE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-01-27 | — | — | US | disclosed |
| EP-3394093-B1 | METHODS OF USING OX40 LIGAND ENCODING POLYNUCLEOTIDES | MODERNATX INC (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20220017898-A1 | OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES | ALPHA ANOMERIC SAS (FR) | 2022-01-20 | — | — | US | disclosed |
| WO-2022011214-A1 | CIRCULAR SIRNAS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| WO-2022006042-A1 | METHODS, COMPOSITIONS, AND KITS FOR NUCLEIC ACID BARCODING OF BIOMOLECULES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-01-06 | — | — | WO | disclosed |
| US-20210403909-A1 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | NOVO NORDISK A/S (DK) | 2021-12-30 | — | — | US | disclosed |
| US-11207416-B2 | Compositions and methods for targeted RNA delivery | VERVE THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11208662-B2 | RNAi inhibition of alpha-ENaC expression | Arrowhead Pharmaceuticals, Inc. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11208658-B2 | Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| EP-3134131-B1 | NUCLEIC ACID VACCINES | MODERNATX INC (US) | 2021-12-22 | — | — | EP | disclosed |
| US-20210388358-A1 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | NOVO NORDISK A/S (DK) | 2021-12-16 | — | — | US | disclosed |
| US-20210388356-A1 | MODIFIED DOUBLE STRANDED OLIGONUCLEOTIDE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-12-16 | — | — | US | disclosed |
| US-11197927-B2 | Human cytomegalovirus vaccine | MODERNATX, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| EP-3919619-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | Alnylam Pharmaceuticals, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| EP-3215522-B1 | T CELL RECEPTORS DIRECTED AGAINST BOB1 AND USES THEREOF | ACADEMISCH ZIEKENHUIS LEIDEN H O D N LEIDS UNIV MEDISCH CENTRUM (NL) | 2021-12-01 | — | — | EP | disclosed |
| EP-3444350-B1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS INC (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3914734-A2 | COMPOSITIONS AND METHOD FOR SYNTHESIZING NUCLEIC ACIDS | President and Fellows of Harvard College (US) | 2021-12-01 | — | — | EP | disclosed |
| US-11186829-B2 | Isolated mammalian somatic cells containing modified RNA encoding OCT4, SOX2, and KLF4 | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-11-30 | — | — | US | disclosed |
| US-11185510-B2 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | MODERNATX, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210346477-A1 | COSTIMULATION OF CHIMERIC ANTIGEN RECEPTORS BY MYD88 AND CD40 POLYPEPTIDES | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2021-11-11 | — | — | US | disclosed |
| EP-3324980-B1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | ALNYLAM PHARMACEUTICALS INC (US) | 2021-11-10 | — | — | EP | disclosed |
| EP-3896164-A1 | POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | ModernaTX, Inc. (US) | 2021-10-20 | — | — | EP | disclosed |
| US-20210318817-A1 | METHODS OF USING OX40 LIGAND ENCODING POLYNUCLEOTIDES | MODERNATX, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210317461-A1 | OLIGONUCLEOTIDE COMPOSITIONS FOR TARGETING CCR2 AND CSF1R AND USES THEREOF | VERSEAU THERAPEUTICS, INC. | 2021-10-14 | — | — | US | disclosed |
| EP-3892727-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GLYCOLATE OXIDASE (HAO1) BY DOUBLE-STRANDED RNA | Dicerna Pharmaceuticals, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| WO-2021202557-A1 | SPHERICAL NUCLEIC ACIDS (SNAS) FOR REGULATION OF FRATAXIN | EXICURE OPERATING COMPANY (US) | 2021-10-07 | — | — | WO | disclosed |
| US-20210299261-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210299221-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2021-09-30 | — | — | US | disclosed |
| US-20210292757-A1 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | NOVO NORDISK A/S (DK) | 2021-09-23 | — | — | US | disclosed |
| US-20210285015-A1 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | HARVARD COLLEGE (US) | 2021-09-16 | — | — | US | disclosed |
| EP-3877524-A1 | MODIFIED DOUBLE STRANDED OLIGONUCLEOTIDES | Alnylam Pharmaceuticals Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| WO-2021178725-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. (US) | 2021-09-10 | — | — | WO | disclosed |
| US-20210277423-A1 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | HARVARD COLLEGE (US) | 2021-09-09 | — | — | US | disclosed |
| US-20210274726-A1 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | HARVARD COLLEGE (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3458590-B9 | POLYNUCLEOTIDES ENCODING -GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | MODERNATX INC (US) | 2021-08-18 | — | — | EP | disclosed |
| EP-3865576-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | Dicerna Pharmaceuticals, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
| EP-3856907-A1 | TRANSTHYRETIN (TTR) IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | Alnylam Pharmaceuticals, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-11077176-B2 | Methods for inducing selective apoptosis | BAYLOR COLLEGE OF MEDICINE (US) | 2021-08-03 | — | — | US | disclosed |
| US-20210230604-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GLYCOLATE OXIDASE (HAO1) BY DOUBLE-STRANDED RNA | NOVO NORDISK A/S (DK) | 2021-07-29 | — | — | US | disclosed |
| EP-3852732-A1 | PEG LIPIDS AND USES THEREOF | ModernaTX, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3854874-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF BETA-CATENIN BY DOUBLE-STRANDED RNA | Dicerna Pharmaceuticals, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3853305-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | ModernaTX, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| US-11071716-B2 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | MODERNATX, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| CN-113164589-A | Compositions and methods for modulating monocyte and macrophage inflammatory phenotype and immunotherapy uses thereof | 维西欧制药公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2021146488-A1 | 4'-O-METHYLENE PHOSPHONATE NUCLEIC ACIDS AND ANALOGUES THEREOF | DICERNA PHARMACEUTICALS, INC. (US) | 2021-07-22 | — | — | WO | disclosed |
| WO-2021146391-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C–P BONDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-22 | — | — | WO | disclosed |
| US-20210220467-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2021-07-22 | — | — | US | disclosed |
| US-11066672-B1 | Methods and compositions for the specific inhibition of transthyretin (TTR) by double stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-11060093-B2 | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210206818-A1 | MESSENGER RIBONUCLEIC ACIDS FOR THE PRODUCTION OF INTRACELLULAR BINDING POLYPEPTIDES AND METHODS OF USE THEREOF | MODERNATX, INC. | 2021-07-08 | — | — | US | disclosed |
| US-11053502-B1 | Therapeutic inhibition of lactate dehydrogenase and agents therefor | DICERNA PHARMACEUTICALS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-11053495-B2 | Multi-targeted single entity conjugates | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-11045540-B2 | Varicella zoster virus (VZV) vaccine | MODERNATX, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20210187097-A1 | BROAD SPECTRUM INFLUENZA VIRUS VACCINE | MODERNATX, INC. (US) | 2021-06-24 | — | — | US | disclosed |
| US-20210189342-A1 | COMPOSITIONS AND METHODS FOR MODULATING MONOCYTE AND MACROPHAGE INFLAMMATORY PHENOTYPES AND IMMUNOTHERAPY USES THEREOF | VERSEAU THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210180068-A1 | THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR | NOVO NORDISK HEALTH CARE AG (CH) | 2021-06-17 | — | — | US | disclosed |
| US-20210180061-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA | NOVO NORDISK A/S (DK) | 2021-06-17 | — | — | US | disclosed |
| WO-2021119402-A1 | COMPOSITIONS AND METHODS FOR LIGHT-DIRECTED BIOMOLECULAR BARCODING | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-06-17 | — | — | WO | disclosed |
| EP-3833762-A1 | OLIGONUCLEOTIDE COMPOSITIONS FOR TARGETING CCR2 AND CSF1R AND USES THEREOF | Verseau Therapeutics, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| WO-2021108291-A1 | SYNTHESIS OF 3'-RNA OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| US-11021709-B2 | Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-06-01 | — | — | US | disclosed |
| US-11019776-B2 | Compositions and methods for modulating immunity in plants | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210145982-A1 | RNA FORMULATIONS | MODERNATX, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-20210147507-A1 | METHODS TO AUGMENT OR ALTER SIGNAL TRANSDUCTION | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2021-05-20 | — | — | US | disclosed |
| US-11007260-B2 | Infectious disease vaccines | MODERNATX, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20210139903-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF COMPLEMENT COMPONENT 5(C5) BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-11000573-B2 | Polynucleotides encoding interleukin-12 (IL12) and uses thereof | MODERNATX, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| US-11001861-B2 | Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1 | MODERNATX, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| US-11003366-B2 | Methods of using OX40 ligand encoding polynucleotides | MODERNATX, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| EP-3813881-A2 | COMPOSITIONS AND METHODS FOR MODULATING MONOCYTE AND MACROPHAGE INFLAMMATORY PHENOTYPES AND IMMUNOTHERAPY USES THEREOF | Verseau Therapeutics, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10993918-B2 | Polynucleotides encoding citrin for the treatment of Citrullinemia type 2 | MODERNATX, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-10973917-B2 | MRNA combination therapy for the treatment of cancer | MODERNATX, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20210095279-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ANTITHROMBIN 3 (AT3) BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. | 2021-04-01 | — | — | US | disclosed |
| EP-3581654-B1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GLYCOLATE OXIDASE (HAO1) BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS INC (US) | 2021-03-31 | — | — | EP | disclosed |
| US-20210087219-A1 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | ALNYLAM PHARMACEUTICALS INC (US) | 2021-03-25 | — | — | US | disclosed |
| US-10954517-B2 | Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3790968-A1 | OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES | Alpha Anomeric SAS (FR) | 2021-03-17 | — | — | EP | disclosed |
| EP-3790970-A1 | EXTRAHEPATIC DELIVERY | Alnylam Pharmaceuticals Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| US-10946035-B2 | Production of stable non-polyadenylated RNAs | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-03-16 | — | — | US | disclosed |
| US-20210062189-A1 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | NOVO NORDISK A/S (DK) | 2021-03-04 | — | — | US | disclosed |
| WO-2021041756-A1 | LIGAND-2'-MODIFIED NUCLEIC ACIDS, SYNTHESIS THEREOF AND INTERMEDIATE COMPOUNDS THEREOF | DICERNA PHARMACEUTICALS, INC. (US) | 2021-03-04 | — | — | WO | disclosed |
| US-20210061843-A1 | MULTIMERIC POLYNUCLEOTIDES AND USES THEREOF | MODERNATX, INC. | 2021-03-04 | — | — | US | disclosed |
| EP-3587579-B1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF BETA-CATENIN BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS INC (US) | 2021-03-03 | — | — | EP | disclosed |
| US-10933127-B2 | Betacoronavirus mRNA vaccine | MODERNATX, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10934346-B2 | Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12 | BELLICUM PHARMACEUTICALS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| CN-112424352-A | Oligonucleotide conjugates comprising 7 '-5' -alpha-anomeric bicyclic sugar nucleosides | 阿尔法阿诺麦里克公司 | 2021-02-26 | — | — | CN | disclosed |
| CN-112400018-A | Extrahepatic delivery | 阿尔尼拉姆医药品有限公司 | 2021-02-23 | — | — | CN | disclosed |
| EP-3774824-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | Bristol-Myers Squibb Company (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10918705-B2 | Costimulation of chimeric antigen receptors by MYD88 and CD40 polypeptides | Bellicum Pharmaceutics, Inc. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20210038529-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2021-02-11 | — | — | US | disclosed |
| US-10913767-B2 | Oligonucleotides comprising acyclic and abasic nucleosides and analogs | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| EP-3569711-B1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | DICERNA PHARMACEUTICALS INC (US) | 2021-02-03 | — | — | EP | disclosed |
| EP-3458590-B1 | POLYNUCLEOTIDES ENCODING -GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | MODERNATX INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-10888608-B2 | Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides | BELLICUM PHARMACEUTICALS, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| WO-2021001739-A1 | TRANSLATIONAL ENHANCERS AND RELATED METHODS | EFFECTOR THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| US-20200405716-A1 | HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA | ACETYLON PHARMACEUTICALS, INC. | 2020-12-31 | — | — | US | disclosed |
| US-20200405844-A1 | COMBINATION HPIV3/HMPV RNA VACCINES | MODERNATX, INC. (US) | 2020-12-31 | — | — | US | disclosed |
| WO-2020257194-A1 | DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| US-10870849-B2 | Extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200376081-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | MODERNATX, INC. | 2020-12-03 | — | — | US | disclosed |
| US-20200368344-A1 | CHIKV RNA VACCINES | MODERNATX, INC. (US) | 2020-11-26 | — | — | US | disclosed |
| WO-2020236600-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| US-20200368343-A1 | ZIKA VIRUS MRNA VACCINES | MODERNATX, INC. (US) | 2020-11-26 | — | — | US | disclosed |
| US-10844381-B2 | Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200362350-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-11-19 | — | — | US | disclosed |
| US-10837013-B2 | Extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200354429-A1 | POLYNUCLEOTIDES ENCODING RELAXIN | MODERNATX, INC. (US) | 2020-11-12 | — | — | US | disclosed |
| WO-2020185312-A9 | COMPOSITIONS AND METHOD FOR SYNTHESIZING NUCLEIC ACIDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-11-12 | — | — | WO | disclosed |
| CN-111849912-A | Method for activating T cells using inducible chimeric polypeptides | 贝里坤制药股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| US-20200338190-A1 | HUMAN CYTOMEGALOVIRUS VACCINE | MODERNATX, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200339996-A1 | ANTI-TNF COMPOUNDS | EXICURE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-10815291-B2 | Polynucleotides encoding immune modulating polypeptides | MODERNATX, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200323964-A1 | PEPTIDES AND NANOPARTICLES FOR INTRACELLULAR DELIVERY OF MRNA | AADIGEN, LLC | 2020-10-15 | — | — | US | disclosed |
| US-20200318118-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF KRAS BY ASYMMETRIC DOUBLE-STRANDED RNA | NOVO NORDISK A/S (DK) | 2020-10-08 | — | — | US | disclosed |
| EP-3718565-A1 | RESPIRATORY VIRUS VACCINES | ModernaTX, Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20200308579-A1 | LIPOSOMAL SPHERICAL NUCLEIC ACID (SNA) CONSTRUCTS PRESENTING ANTISENSE OLIGONUCLEOTIDES (ASO) FOR SPECIFIC KNOCKDOWN OF INTERLEUKIN 17 RECEPTOR MRNA | EXICURE, INC. (US) | 2020-10-01 | — | — | US | disclosed |
| US-20200289639-A1 | CHIKUNGUNYA VIRUS RNA VACCINES | MODERNATX, INC. (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200289638-A1 | ZIKA VIRUS RNA VACCINES | MODERNATX, INC. (US) | 2020-09-17 | — | — | US | disclosed |
| WO-2020185312-A2 | COMPOSITIONS AND METHOD FOR SYNTHESIZING NUCLEIC ACIDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-09-17 | — | — | WO | disclosed |
| US-20200282046-A1 | BETACORONAVIRUS MRNA VACCINE | MODERNATX, INC. (US) | 2020-09-10 | — | — | US | disclosed |
| US-10760080-B2 | Anti-TNF compounds | EXICURE, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| EP-2968502-B1 | METHODS FOR CONTROLLING T CELL PROLIFERATION | BELLICUM PHARMACEUTICALS INC (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3234144-B1 | METHODS FOR CONTROLLED ELIMINATION OF THERAPEUTIC CELLS | BELLICUM PHARMACEUTICALS INC (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3697447-A1 | PEPTIDES AND NANOPARTICLES FOR INTRACELLULAR DELIVERY OF MRNA | Aadigen, LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10752899-B2 | Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200262856-A1 | UTILITY OF NEMATODE SMALL MOLECULES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-08-20 | — | — | US | disclosed |
| US-20200254086-A1 | EFFICACIOUS MRNA VACCINES | Moderna TX, Inc. (US) | 2020-08-13 | — | — | US | disclosed |
| US-10738311-B2 | Therapeutic inhibition of lactate dehydrogenase and agents therefor | DICERNA PHARMACEUTICALS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200246453-A1 | HUMAN CYTOMEGALOVIRUS RNA VACCINES | MODERNATX, INC. (US) | 2020-08-06 | — | — | US | disclosed |
| US-10730924-B2 | Polynucleotides encoding relaxin | MODERNATX, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| CN-106132423-B | Method for activating T cells using inducible chimeric polypeptides | 贝里坤制药股份有限公司 | 2020-07-31 | — | — | CN | disclosed |
| CN-105209065-B | Method for controlling T cell proliferation | 贝里坤制药股份有限公司 | 2020-07-31 | — | — | CN | disclosed |
| US-20200237886-A1 | COSTIMULATION OF CHIMERIC ANTIGEN RECEPTORS BY MYD88 AND CD40 POLYPEPTIDES | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2020-07-30 | — | — | US | disclosed |
| US-20200230216-A1 | METHODS FOR INDUCING PARTIAL APOPTOSIS USING CASPASE POLYPEPTIDES | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2020-07-23 | — | — | US | disclosed |
| US-10716846-B2 | Human cytomegalovirus RNA vaccines | MODERNATX, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-10709779-B2 | Nucleic acid vaccines | MODERNATX, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10702600-B1 | Betacoronavirus mRNA vaccine | MODERNATX, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10704049-B2 | Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-07-07 | — | — | US | disclosed |
| US-10702597-B2 | CHIKV RNA vaccines | MODERNATX, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10702599-B2 | HPIV3 RNA vaccines | MODERNATX, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200206362-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | Moderna TX, Inc. (US) | 2020-07-02 | — | — | US | disclosed |
| US-10695419-B2 | Human cytomegalovirus vaccine | MODERNATX, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20200197510-A1 | RESPIRATORY VIRUS VACCINES | MODERNATX, INC. (US) | 2020-06-25 | — | — | US | disclosed |
| EP-3668981-A1 | TUNABLE REVERSIR TM COMPOUNDS | Alnylam Pharmaceuticals, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3668522-A2 | EFFICACIOUS MRNA VACCINES | Modernatx, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| US-10689647-B2 | Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20200188521-A1 | SYNTHESIS OF SPHERICAL NUCLEIC ACIDS USING LIPOPHILIC MOIETIES | EXICURE, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| EP-3666896-A1 | THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR | Dicerna Pharmaceuticals, Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| US-20200181648-A1 | METHODS AND COMPOSITIONS TO INCREASE HUMAN SOMATIC CELL NUCLEAR TRANSFER (SCNT) EFFICIENCY BY REMOVING HISTONE H3-LYSINE TRIMETHYLATION, AND DERIVATION OF HUMAN NT-ESC | CHILDRENS MEDICAL CENTER (US) | 2020-06-11 | — | — | US | disclosed |
| US-10676742-B2 | Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-10675342-B2 | Chikungunya virus RNA vaccines | MODERNATX, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| US-20200157550-A1 | RNAi Inhibition of Alpha-ENaC Expression | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2020-05-21 | — | — | US | disclosed |
| US-20200149052-A1 | POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | ARES CAPITAL CORPORATION, AS AGENT | 2020-05-14 | — | — | US | disclosed |
| US-10646549-B2 | Polynucleotides encoding interleukin-12 (IL12) and uses thereof | MODERNATX, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20200129608-A1 | RESPIRATORY SYNCYTIAL VIRUS VACCINE | MODERNATX, INC. (US) | 2020-04-30 | — | — | US | disclosed |
| US-20200129615-A1 | HERPES SIMPLEX VIRUS VACCINE | MODERNATX, INC. (US) | 2020-04-30 | — | — | US | disclosed |
| US-20200131498-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE | MODERNATX, INC. | 2020-04-30 | — | — | US | disclosed |
| EP-3641810-A1 | HERPES SIMPLEX VIRUS VACCINE | Modernatx, Inc. (US) | 2020-04-29 | — | — | EP | disclosed |
| EP-3638215-A1 | RNA FORMULATIONS | Modernatx, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| US-20200113844-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | MODERNATX, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-10612023-B2 | Methods and compositions for the specific inhibition of β-catenin by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2020-04-07 | — | — | US | disclosed |
| WO-2020069055-A1 | TRANSTHYRETIN (TTR) IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| US-20200102363-A1 | POLYNUCLEOTIDES ENCODING TETHERED INTERLEUKIN-12 (IL12) POLYPEPTIDES AND USES THEREOF | MODERNATX, INC. (US) | 2020-04-02 | — | — | US | disclosed |
| WO-2020061284-A1 | PEG LIPIDS AND USES THEREOF | MODERNATX, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2020061295-A1 | HIGH-PURITY PEG LIPIDS AND USES THEREOF | MODERNATX, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| EP-3625246-A1 | POLYNUCLEOTIDES ENCODING TETHERED INTERLEUKIN-12 (IL12) POLYPEPTIDES AND USES THEREOF | ModernaTX, Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| US-20200085916-A1 | POLYNUCLEOTIDES ENCODING PORPHOBILINOGEN DEAMINASE FOR THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA | MODERNATX, INC. | 2020-03-19 | — | — | US | disclosed |
| EP-3621988-A1 | METHODS TO AUGMENT OR ALTER SIGNAL TRANSDUCTION | Bellicum Pharmaceuticals, Inc. (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20200078314-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | MODERNATX, INC. (US) | 2020-03-12 | — | — | US | disclosed |
| EP-3204497-B1 | THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR | DICERNA PHARMACEUTICALS INC (US) | 2020-03-11 | — | — | EP | disclosed |
| US-20200071689-A1 | RNA AFFINITY PURIFICATION | MODERNATX, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200069793-A1 | VARICELLA ZOSTER VIRUS (VZV) VACCINE | MODERNATX, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| EP-3004329-B1 | METHODS FOR INDUCING PARTIAL APOPTOSIS USING CASPASE POLYPEPTIDES | BELLICUM PHARMACEUTICALS INC (US) | 2020-03-04 | — | — | EP | disclosed |
| US-10570388-B2 | Phosphate replacement MRNA cap analogs | MODERNATX, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20200054678-A1 | T CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF | LEIDEN UNIVERSITY MEDICAL CENTER (NL) | 2020-02-20 | — | — | US | disclosed |
| US-20200054747-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | ARES CAPITAL CORPORATION, AS AGENT | 2020-02-20 | — | — | US | disclosed |
| US-20200054737-A1 | HERPES SIMPLEX VIRUS VACCINE | Modema TX, Inc. (US) | 2020-02-20 | — | — | US | disclosed |
| EP-3609534-A1 | BROAD SPECTRUM INFLUENZA VIRUS VACCINE | ModernaTX, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| US-10563195-B2 | Phosphate replacement mRNA cap analogs | MODERNATX, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| WO-2020033791-A1 | OLIGONUCLEOTIDE COMPOSITIONS FOR TARGETING CCR2 AND CSF1R AND USES THEREOF | VERSEAU THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| US-20200048659-A1 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2020-02-13 | — | — | US | disclosed |
| EP-3608408-A1 | METHODS FOR CONTROLLED ACTIVATION OR ELIMINATION OF THERAPEUTIC CELLS | Bellicum Pharmaceuticals, Inc. (US) | 2020-02-12 | — | — | EP | disclosed |
| US-10557134-B2 | Protection of barcodes during DNA amplification using molecular hairpins | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-02-11 | — | — | US | disclosed |
| US-10556018-B2 | Compositions and methods for delivery of agents | ARES CAPITAL CORPORATION, AS AGENT | 2020-02-11 | — | — | US | disclosed |
| US-20200038499-A1 | RNA BACTERIAL VACCINES | MODERNATX, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| EP-3604533-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | Arbutus Biopharma Corporation (CA) | 2020-02-05 | — | — | EP | disclosed |
| US-20200030421-A1 | METHODS FOR INDUCING SELECTIVE APOPTOSIS | BAYLOR COLLEGE OF MEDICINE | 2020-01-30 | — | — | US | disclosed |
| US-20200031862-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | DICERNA PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | disclosed |
| US-10543269-B2 | hMPV RNA vaccines | MODERNATX, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-10544418-B2 | RNAi inhibition of alpha-ENaC expression | Arrowhead Pharmaceuticals, Inc. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190359987-A1 | COMPOSITION AND METHOD FOR OLIGONUCLEOTIDE DELIVERY | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-11-28 | — | — | US | disclosed |
| US-20190351040-A1 | RNA CANCER VACCINES | MODERNATX, INC. (US) | 2019-11-21 | — | — | US | disclosed |
| EP-3569253-A1 | METHODS FOR INDUCING PARTIAL APOPTOSIS USING CASPASE POLYPEPTIDES | Bellicum Pharmaceuticals, Inc. (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-3569711-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | Dicerna Pharmaceuticals, Inc. (US) | 2019-11-20 | — | — | EP | disclosed |
| US-10479813-B2 | Utility of nematode small molecules | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-11-19 | — | — | US | disclosed |
| WO-2019217459-A1 | EXTRAHEPATIC DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019215333-A1 | OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES | ALPHA ANOMERIC SAS (FR) | 2019-11-14 | — | — | WO | disclosed |
| EP-3563682-A1 | THE UTILITY OF NEMATODE SMALL MOLECULES | California Institute of Technology (US) | 2019-11-06 | — | — | EP | disclosed |
| US-10465195-B2 | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20190330630-A1 | ENDOSOMAL CLEAVABLE LINKERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-10-31 | — | — | US | disclosed |
| US-20190321464-A1 | HUMAN CYTOMEGALOVIRUS RNA VACCINES | MODERNATX, INC. (US) | 2019-10-24 | — | — | US | disclosed |
| US-20190322694-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | THE SCRIPPS RESEARCH INSTITUTE | 2019-10-24 | — | — | US | disclosed |
| US-20190323014-A1 | THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR | DICERNA PHARMACEUTICALS, INC. (US) | 2019-10-24 | — | — | US | disclosed |
| EP-3555289-A1 | RNA AFFINITY PURIFICATION | ModernaTX, Inc. (US) | 2019-10-23 | — | — | EP | disclosed |
| US-10449244-B2 | Zika RNA vaccines | MODERNATX, INC. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190314493-A1 | HUMAN CYTOMEGALOVIRUS VACCINE | MODERNATX, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| WO-2019200273-A1 | NOVEL PHOSPHOROUS (V)-BASED REAGENTS, PROCESSES FOR THE PREPARATION THEREOF, AND THEIR USE IN MAKING STEREO-DEFINED ORGANOPHOSHOROUS (V) COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-17 | — | — | WO | disclosed |
| EP-3553181-A1 | NUCLEIC ACID AMPLIFICATION AND USE THEREOF | Accugenomics, Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| US-10435692-B2 | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190298657-A1 | Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency | MODERNATX, INC. (US) | 2019-10-03 | — | — | US | disclosed |
| US-20190300906-A1 | POLYNUCLEOTIDES ENCODING GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE FOR THE TREATMENT OF GALACTOSEMIA TYPE 1 | MODERNATX, INC. (US) | 2019-10-03 | — | — | US | disclosed |
| US-20190300963-A1 | MIRNA EXPRESSION SIGNATURE IN THE CLASSIFICATION OF THYROID TUMORS | ROSETTA GENOMICS LTD. (IL) | 2019-10-03 | — | — | US | disclosed |
| US-20190298658-A1 | Polynucleotides Encoding Cystic Fibrosis Transmembrane Conductance Regulator for the Treatment of Cystic Fibrosis | MODERNATX, INC. (US) | 2019-10-03 | — | — | US | disclosed |
| US-10428106-B2 | Phosphate replacement mRNA cap analogs | MODERNATX, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10426738-B2 | Polynucleotides encoding methylmalonyl-CoA mutase | MODERNATX, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190275170-A1 | POLYNUCLEOTIDES ENCODING JAGGED1 FOR THE TREATMENT OF ALAGILLE SYNDROME | MODERNATX, INC. (US) | 2019-09-12 | — | — | US | disclosed |
| US-10407683-B2 | Circular polynucleotides | MODERNATX, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-10406112-B2 | Polynucleotides encoding methylmalonyl-CoA mutase | MODERNATX, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-10406113-B2 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | MODERNATX, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-3169335-B1 | CIRCULAR POLYNUCLEOTIDES | MODERNA THERAPEUTICS INC (US) | 2019-08-28 | — | — | EP | disclosed |
| EP-3528821-A1 | HUMAN CYTOMEGALOVIRUS VACCINE | ModernaTX, Inc. (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20190256901-A1 | NUCLEIC ACID AMPLIFICATION AND USE THEREOF | ACCUGENOMICS INC (US) | 2019-08-22 | — | — | US | disclosed |
| US-20190256899-A1 | NUCLEIC ACID AMPLIFICATION AND USE THEREOF | ACCUGENOMICS INC (US) | 2019-08-22 | — | — | US | disclosed |
| US-10383937-B2 | Human cytomegalovirus RNA vaccines | MODERNATX, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10383951-B2 | Methods of using OX40 ligand encoding polynucleotides | MODERNATX, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10385337-B2 | Oligonucleotide end caps | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20190248864-A1 | POLYNUCLEOTIDES ENCODING LOW DENSITY LIPOPROTEIN RECEPTOR | MODERNATX, INC. | 2019-08-15 | — | — | US | disclosed |
| US-10379767-B2 | Methods of using OX40 ligand encoding polynucleotides | MODERNATX, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-10378016-B2 | Composition and method for oligonucleotide delivery | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-08-13 | — | — | US | disclosed |
| US-20190241658-A1 | Therapeutic mRNAs encoding anti CTLA-4 antibodies | MODERNATX INC (US) | 2019-08-08 | — | — | US | disclosed |
| US-20190240317-A1 | HPIV3 RNA VACCINES | MODERNATX, INC. (US) | 2019-08-08 | — | — | US | disclosed |
| US-10370655-B2 | Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20190233815-A1 | METHODS AND COMPOSITIONS FOR TREATING INSECTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-20190233485-A1 | T CELL RECEPTORS DIRECTED AGAINST BOB1 AND USES THEREOF | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2019-08-01 | — | — | US | disclosed |
| US-20190225644-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | MODERNATX, INC. | 2019-07-25 | — | — | US | disclosed |
| WO-2019143910-A1 | MULTIMERIC POLYNUCLEOTIDES AND USES THEREOF | MODERNATX, INC. (US) | 2019-07-25 | — | — | WO | disclosed |
| US-20190216917-A1 | HMPV RNA VACCINES | MODERNATX, INC. (US) | 2019-07-18 | — | — | US | disclosed |
| US-20190218546-A1 | MRNA CAP ANALOGS WITH MODIFIED PHOSPHATE LINKAGE | MODERNATX, INC. | 2019-07-18 | — | — | US | disclosed |
| US-20190218550-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF COMPLEMENT COMPONENT 5(C5) BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2019-07-18 | — | — | US | disclosed |
| US-10351854-B2 | Therapeutic inhibition of lactate dehydrogenase and agents therefor | DICERNA PHARMACEUTICALS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190211368-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | MODERNATX, INC. | 2019-07-11 | — | — | US | disclosed |
| US-20190211340-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GLYCOLATE OXIDASE (HAO1) BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | US | disclosed |
| US-20190211338-A1 | ANTI-TNF COMPOUNDS | EXICURE, INC. (US) | 2019-07-11 | — | — | US | disclosed |
| EP-3234132-B1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | DICERNA PHARMACEUTICALS INC (US) | 2019-07-10 | — | — | EP | disclosed |
| US-10344265-B2 | Sustained polypeptide expression from synthetic, modified RNAs and uses thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-07-09 | — | — | US | disclosed |
| EP-2967081-B1 | MODIFIED CASPASE POLYPEPTIDES AND USES THEREOF | BELLICUM PHARMACEUTICALS INC (US) | 2019-07-03 | — | — | EP | disclosed |
| EP-3087184-B1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GLYCOLATE OXIDASE (HAO1) BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS INC (US) | 2019-07-03 | — | — | EP | disclosed |
| US-10335486-B2 | MRNA combination therapy for the treatment of cancer | MODERNATX, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190194665-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GLYCOLATE OXIDASE (HAO1) BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190192653-A1 | COMPOSITIONS AND METHODS FOR TOLERIZING CELLULAR SYSTEMS | MODERNA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-10323076-B2 | Polynucleotides encoding low density lipoprotein receptor | MODERNATX, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-10322090-B2 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | MODERNATX, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-10322091-B2 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | MODERNATX, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20190175690-A1 | COMPOSITIONS AND METHODS FOR CARDIAC REPAIR | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-06-13 | — | — | US | disclosed |
| US-20190175517-A1 | POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 | ARES CAPITAL CORPORATION, AS AGENT | 2019-06-13 | — | — | US | disclosed |
| US-20190167811-A1 | LIPID COMPOSITIONS AND THEIR USES FOR INTRATUMORAL POLYNUCLEOTIDE DELIVERY | MODERNATX, INC. | 2019-06-06 | — | — | US | disclosed |
| EP-3234145-B1 | METHODS FOR CONTROLLED ACTIVATION OR ELIMINATION OF THERAPEUTIC CELLS | BELLICUM PHARMACEUTICALS INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-20190153014-A1 | UTILITY OF NEMATODE SMALL MOLECULES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-05-23 | — | — | US | disclosed |
| US-10293023-B2 | Method of altering vascular permeability and uses thereof | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-05-21 | — | — | US | disclosed |
| US-20190144859-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF TRANSTHYRETIN (TTR) BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2019-05-16 | — | — | US | disclosed |
| US-20190142739-A1 | TOPICAL ADMINISTRATION OF THERAPEUTIC AGENTS AND OLIGONUCLEOTIDE FORMULATIONS | EXICURE, INC. (US) | 2019-05-16 | — | — | US | disclosed |
| US-10285950-B2 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | MODERNATX, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20190125839-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2019-05-02 | — | — | US | disclosed |
| EP-3037538-B1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF BETA-CATENIN BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS INC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-10272150-B2 | Combination PIV3/hMPV RNA vaccines | MODERNATX, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| WO-2019079215-A1 | PEPTIDES AND NANOPARTICLES FOR INTRACELLULAR DELIVERY OF MRNA | AADIGEN, LLC (US) | 2019-04-25 | — | — | WO | disclosed |
| US-20190117733-A1 | EFFICIENT PROTEIN EXPRESSION IN VIVO USING MODIFIED RNA (MOD-RNA) | THE GENERAL HOSPITAL CORPORATION (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190117798-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2019-04-25 | — | — | US | disclosed |
| US-10266848-B2 | Methods and compositions to increase somatic cell nuclear transfer (SCNT) efficiency by removing histone H3-lysine trimethylation | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-04-23 | — | — | US | disclosed |
| US-20190114089-A1 | METHODS OF USING OX40 LIGAND ENCODING POLYNUCLEOTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2019-04-18 | — | — | US | disclosed |
| US-20190111003-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2019-04-18 | — | — | US | disclosed |
| US-20190114090-A1 | METHODS OF USING OX40 LIGAND ENCODING POLYNUCLEOTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2019-04-18 | — | — | US | disclosed |
| US-20190105280-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2019-04-11 | — | — | US | disclosed |
| US-20190105281-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2019-04-11 | — | — | US | disclosed |
| EP-3458474-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3458106-A1 | POLYNUCLEOTIDES ENCODING LIPOPROTEIN LIPASE FOR THE TREATMENT OF HYPERLIPIDEMIA | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3458108-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | ModernaTX, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3458107-A1 | POLYNUCLEOTIDES ENCODING JAGGED1 FOR THE TREATMENT OF ALAGILLE SYNDROME | ModernaTX, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3458034-A2 | POLYNUCLEOTIDES ENCODING RELAXIN | ModernaTX, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3460064-A1 | EFFICIENT PROTEIN EXPRESSION IN VIVO USING MODIFIED RNA (MOD-RNA) | The General Hospital Corporation d/b/a Massachusetts General Hospital (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3458081-A1 | POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3458092-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3458104-A1 | POLYNUCLEOTIDES ENCODING PORPHOBILINOGEN DEAMINASE FOR THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3458105-A1 | POLYNUCLEOTIDES ENCODING GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE FOR THE TREATMENT OF GALACTOSEMIA TYPE 1 | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3458590-A1 | POLYNUCLEOTIDES ENCODING -GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| EP-3458083-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | Modernatx, Inc. (US) | 2019-03-27 | — | — | EP | disclosed |
| US-10238731-B2 | Chikagunya virus RNA vaccines | MODERNATX, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-3452598-A1 | LIPOSOMAL SPHERICAL NUCLEIC ACID (SNA) CONSTRUCTS PRESENTING ANTISENSE OLIGONUCLEOTIDES (ASO) FOR SPECIFIC KNOCKDOWN OF INTERLEUKIN 17 RECEPTOR MRNA | Exicure, Inc. (US) | 2019-03-13 | — | — | EP | disclosed |
| WO-2019036670-A2 | EFFICACIOUS MRNA VACCINES | MODERNATX, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019036612-A1 | TUNABLE REVERSIR TM COMPOUNDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20190054112-A1 | POLYNUCLEOTIDE FORMULATIONS FOR USE IN THE TREATMENT OF RENAL DISEASES | MODERNATX, INC. | 2019-02-21 | — | — | US | disclosed |
| US-20190053451-A1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. | 2019-02-21 | — | — | US | disclosed |
| EP-3444350-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA | Dicerna Pharmaceuticals, Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3443001-A2 | REGULATED BIOCIRCUIT SYSTEMS | Obsidian Therapeutics, Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-3442590-A2 | LIPID COMPOSITIONS AND THEIR USES FOR INTRATUMORAL POLYNUCLEOTIDE DELIVERY | Modernatx, Inc. (US) | 2019-02-20 | — | — | EP | disclosed |
| US-10207010-B2 | Compositions and methods for delivery of agents | MODERNATX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10208319-B2 | Therapeutic uses of genome editing with CRISPR/Cas systems | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-02-19 | — | — | US | disclosed |
| US-10208310-B2 | Anti-TNF compounds | EXICURE, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10189880-B2 | T cell receptors directed against Bob1 and uses thereof | LEIDEN UNIVERSITY MEDICAL CENTER (NL) | 2019-01-29 | — | — | US | disclosed |
| US-10190118-B2 | Methods and compositions for treating insects | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20190022019-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | MODERNATX INC (US) | 2019-01-24 | — | — | US | disclosed |
| US-10183963-B2 | Utility of nematode small molecules | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-01-22 | — | — | US | disclosed |
| US-20190016781-A1 | POLYNUCLEOTIDES ENCODING IMMUNE MODULATING POLYPEPTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2019-01-17 | — | — | US | disclosed |
| US-20190015501-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20190008887-A1 | MULTIMERIC MRNA | ModernaTX Inc. (US) | 2019-01-10 | — | — | US | disclosed |
| US-20190008947-A1 | CHIKUNGUNYA VIRUS RNA VACCINES | MODERNATX, INC. (US) | 2019-01-10 | — | — | US | disclosed |
| US-20190008948-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2019-01-10 | — | — | US | disclosed |
| US-20190008938-A1 | CONCATEMERIC PEPTIDE EPITOPE RNAS | MODERNATX, INC. (US) | 2019-01-10 | — | — | US | disclosed |
| US-20190008946-A1 | ZIKA VIRUS RNA VACCINES | MODERNATX, INC. (US) | 2019-01-10 | — | — | US | disclosed |
| EP-3424939-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | Alnylam Pharmaceuticals Inc. (US) | 2019-01-09 | — | — | EP | disclosed |
| US-10172808-B2 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | MODERNATX, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20190002879-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF BETA-CATENIN BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. | 2019-01-03 | — | — | US | disclosed |
| US-20190000959-A1 | NUCLEIC ACID VACCINES | MODERNATX, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| US-20190000932-A1 | POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | MODERNATX, INC. | 2019-01-03 | — | — | US | disclosed |
| US-20190000933-A1 | POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | ARES CAPITAL CORPORATION, AS AGENT | 2019-01-03 | — | — | US | disclosed |
| US-20190002890-A1 | POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | ARES CAPITAL CORPORATION, AS AGENT | 2019-01-03 | — | — | US | disclosed |
| US-20180369374-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | ARES CAPITAL CORPORATION, AS AGENT | 2018-12-27 | — | — | US | disclosed |
| US-20180371047-A1 | POLYNUCLEOTIDES ENCODING RELAXIN | MODERNATX, INC. (US) | 2018-12-27 | — | — | US | disclosed |
| WO-2018231990-A2 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-COA MUTASE | MODERNATX, INC. (US) | 2018-12-20 | — | — | WO | disclosed |
| WO-2018232357-A1 | RNA FORMULATIONS | MODERNATX, INC. (US) | 2018-12-20 | — | — | WO | disclosed |
| US-20180363008-A1 | METHODS AND COMPOSITIONS TO INCREASE SOMATIC CELL NUCLEAR TRANSFER (SCNT) EFFICIENCY BY REMOVING HISTONE H3-LYSINE TRIMETHYLATION | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2018-12-20 | — | — | US | disclosed |
| US-10150965-B2 | Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2018-12-11 | — | — | US | disclosed |
| US-20180344839-A1 | CHIKV RNA VACCINES | MODERNATX, INC. (US) | 2018-12-06 | — | — | US | disclosed |
| US-20180344838-A1 | DENV RNA VACCINES | MODERNATX, INC. (US) | 2018-12-06 | — | — | US | disclosed |
| US-10143723-B2 | Methods of using OX40 ligand encoding polynucleotides | MODERNATX, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| EP-3405579-A1 | MESSENGER RIBONUCLEIC ACIDS FOR THE PRODUCTION OF INTRACELLULAR BINDING POLYPEPTIDES AND METHODS OF USE THEREOF | Modernatx, Inc. (US) | 2018-11-28 | — | — | EP | disclosed |
| US-10136595-B2 | Compositions and methods for modulating immunity in plants | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| WO-2018213731-A1 | POLYNUCLEOTIDES ENCODING TETHERED INTERLEUKIN-12 (IL12) POLYPEPTIDES AND USES THEREOF | MODERNATX, INC. (US) | 2018-11-22 | — | — | WO | disclosed |
| US-10131912-B2 | Extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-10131908-B2 | 5′ phosphate mimics | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180326045-A1 | COMBINATION PIV3/HMPV RNA VACCINES | MODERNATX, INC. (US) | 2018-11-15 | — | — | US | disclosed |
| WO-2018208849-A1 | METHODS TO AUGMENT OR ALTER SIGNAL TRANSDUCTION | BELLICUM PHARMACEUTICALS, INC. (US) | 2018-11-15 | — | — | WO | disclosed |
| EP-3400023-A1 | THERAPEUTIC MRNAS ENCODING ANTI CTLA-4 ANTIBODIES | ModernaTX, Inc. (US) | 2018-11-14 | — | — | EP | disclosed |
| EP-2513334-B1 | DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | DICERNA PHARMACEUTICALS INC (US) | 2018-11-14 | — | — | EP | disclosed |
| US-10124055-B2 | Zika virus RNA vaccines | MODERNATX, INC. (US) | 2018-11-13 | — | — | US | disclosed |
| US-20180318385-A1 | METHODS OF USING OX40 LIGAND ENCODING POLYNUCLEOTIDES | MODERNATX, INC. (US) | 2018-11-08 | — | — | US | disclosed |
| US-20180318229-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2018-11-08 | — | — | US | disclosed |
| US-20180318409-A1 | CANCER VACCINES | MODERNATX, INC. (US) | 2018-11-08 | — | — | US | disclosed |
| EP-2341943-B1 | COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DSRNA POSSESSING MODIFICATIONS | DICERNA PHARMACEUTICALS INC (US) | 2018-11-07 | — | — | EP | disclosed |
| US-20180312535-A1 | PHOSPHATE REPLACEMENT MRNA CAP ANALOGS | ARES CAPITAL CORPORATION, AS AGENT | 2018-11-01 | — | — | US | disclosed |
| US-20180311336-A1 | BROAD SPECTRUM INFLUENZA VIRUS VACCINE | Moderna TX, Inc. (US) | 2018-11-01 | — | — | US | disclosed |
| WO-2018200737-A1 | HERPES SIMPLEX VIRUS VACCINE | MODERNATX, INC. (US) | 2018-11-01 | — | — | WO | disclosed |
| WO-2018201090-A1 | SYNTHESIS OF SPHERICAL NUCLEIC ACIDS USING LIPOPHILIC MOIETIES | EXICURE, INC. (US) | 2018-11-01 | — | — | WO | disclosed |
| EP-3394093-A1 | METHODS OF USING OX40 LIGAND ENCODING POLYNUCLEOTIDES | Modernatx, Inc. (US) | 2018-10-31 | — | — | EP | disclosed |
| US-20180303929-A1 | HERPES SIMPLEX VIRUS VACCINE | Moderna TX, Inc. (US) | 2018-10-25 | — | — | US | disclosed |
| US-20180305393-A1 | PHOSPHATE REPLACEMENT MRNA CAP ANALOGS | ARES CAPITAL CORPORATION, AS AGENT | 2018-10-25 | — | — | US | disclosed |
| EP-3390434-A2 | DUAL CONTROLS FOR THERAPEUTIC CELL ACTIVATION OR ELIMINATION | Bellicum Pharmaceuticals, Inc. (US) | 2018-10-24 | — | — | EP | disclosed |
| EP-3390630-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | Modernatx, Inc. (US) | 2018-10-24 | — | — | EP | disclosed |
| US-20180296662-A1 | SEXUALLY TRANSMITTED DISEASE VACCINES | MODERNATX, INC. (US) | 2018-10-18 | — | — | US | disclosed |
| US-20180298405-A1 | METHODS AND COMPOSITIONS TO INCREASE HUMAN SOMATIC CELL NUCLEAR TRANSFER (SCNT) EFFICIENCY BY REMOVING HISTONE H3-LYSINE TRIMETHYLATION, AND DERIVATION OF HUMAN NT-ESC | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2018-10-18 | — | — | US | disclosed |
| EP-3386484-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20180291055-A1 | PHOSPHATE REPLACEMENT MRNA CAP ANALOGS | ARES CAPITAL CORPORATION, AS AGENT | 2018-10-11 | — | — | US | disclosed |
| US-20180289838-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | ARES CAPITAL CORPORATION, AS AGENT | 2018-10-11 | — | — | US | disclosed |
| US-20180291383-A1 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2018-10-11 | — | — | US | disclosed |
| US-20180291379-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GLYCOLATE OXIDASE (HAO1) BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2018-10-11 | — | — | US | disclosed |
| US-20180291374-A1 | INHIBITORS OF MICRORNAs miR-155, miR-103, miR-105 and miR-107 THAT REGULATE PRODUCTION OF ATRIAL NATRIURETIC PEPTIDE (ANP) AS THERAPEUTICS AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2018-10-11 | — | — | US | disclosed |
| US-20180289792-A1 | SEXUALLY TRANSMITTED DISEASE VACCINES | ModernaTX. Inc. (US) | 2018-10-11 | — | — | US | disclosed |
| US-20180291400-A1 | METHODS AND COMPOSITIONS TO INCREASE HUMAN SOMATIC CELL NUCLEAR TRANSFER (SCNT) EFFICIENCY BY REMOVING HISTONE H3-LYSINE TRIMETHYLATION, AND DERIVATION OF HUMAN NT-ESC | CHILDRENS MEDICAL CENTER (US) | 2018-10-11 | — | — | US | disclosed |
| US-20180282723-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ANTITHROMBIN 3 (AT3) BY DOUBLE-STRANDED RNA | Dicerna Pharmaaceuticals, Inc. (US) | 2018-10-04 | — | — | US | disclosed |
| US-20180280496-A1 | ZIKA RNA VACCINES | MODERNATX, INC. (US) | 2018-10-04 | — | — | US | disclosed |
| US-20180282730-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-10-04 | — | — | US | disclosed |
| US-10086043-B2 | Efficient protein expression in vivo using modified RNA (MOD-RNA) | THE GENERAL HOSPITAL CORPORATION (US) | 2018-10-02 | — | — | US | disclosed |
| US-20180273977-A1 | MULTIMERIC MRNA | MODERNATX, INC. (US) | 2018-09-27 | — | — | US | disclosed |
| US-20180271970-A1 | RESPIRATORY SYNCYTIAL VIRUS VACCINE | MODERNATX, INC. (US) | 2018-09-27 | — | — | US | disclosed |
| US-20180271961-A1 | METHODS FOR INDUCING SELECTIVE APOPTOSIS | BAYLOR COLLEGE OF MEDICINE | 2018-09-27 | — | — | US | disclosed |
| US-20180271975-A1 | HUMAN CYTOMEGALOVIRUS RNA VACCINES | MODERNATX, INC. (US) | 2018-09-27 | — | — | US | disclosed |
| US-20180271795-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | ARES CAPITAL CORPORATION, AS AGENT | 2018-09-27 | — | — | US | disclosed |
| WO-2018175783-A1 | RNA BACTERIAL VACCINES | MODERNATX, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| WO-2018170245-A1 | BROAD SPECTRUM INFLUENZA VIRUS VACCINE | MODERNATX, INC. (US) | 2018-09-20 | — | — | WO | disclosed |
| WO-2018170270-A1 | VARICELLA ZOSTER VIRUS (VZV) VACCINE | MODERNATX, INC. (US) | 2018-09-20 | — | — | WO | disclosed |
| WO-2018170260-A1 | RESPIRATORY SYNCYTIAL VIRUS VACCINE | MODERNATX, INC. (US) | 2018-09-20 | — | — | WO | disclosed |
| WO-2018170256-A1 | HERPES SIMPLEX VIRUS VACCINE | MODERNATX, INC. (US) | 2018-09-20 | — | — | WO | disclosed |
| US-20180265566-A1 | METHODS FOR CONTROLLING T CELL PROLIFERATION | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2018-09-20 | — | — | US | disclosed |
| US-20180258411-A1 | COMPOSITIONS AND METHODS FOR GENOME EDITING | TVA (ABC), LLC | 2018-09-13 | — | — | US | disclosed |
| US-10072263-B2 | Methods and compositions for the specific inhibition of beta-catenin by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2018-09-11 | — | — | US | disclosed |
| US-20180251746-A1 | MODIFIED CASPASE POLYPEPTIDES AND USES THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2018-09-06 | — | — | US | disclosed |
| US-10064934-B2 | Combination PIV3/hMPV RNA vaccines | MODERNATX, INC. (US) | 2018-09-04 | — | — | US | disclosed |
| US-10064935-B2 | Human cytomegalovirus RNA vaccines | MODERNATX, INC. (US) | 2018-09-04 | — | — | US | disclosed |
| US-20180243385-A1 | METHODS FOR INDUCING SELECTIVE APOPTOSIS | BAYLOR COLLEGE OF MEDICINE | 2018-08-30 | — | — | US | disclosed |
| US-20180243384-A1 | METHODS FOR INDUCING PARTIAL APOPTOSIS USING CASPASE POLYPEPTIDES | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2018-08-30 | — | — | US | disclosed |
| EP-3364949-A1 | CANCER VACCINES | ModernaTX, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| EP-3365007-A2 | BROAD SPECTRUM INFLUENZA VIRUS VACCINE | ModernaTX, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| EP-3364983-A2 | RESPIRATORY VIRUS VACCINES | ModernaTX, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| EP-3364982-A2 | SEXUALLY TRANSMITTED DISEASE VACCINES | ModernaTX, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| EP-3365009-A1 | HERPES SIMPLEX VIRUS VACCINE | ModernaTX, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| EP-3365008-A1 | RESPIRATORY SYNCYTIAL VIRUS VACCINE | ModernaTX, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| EP-3364980-A1 | NUCLEIC ACID VACCINES FOR VARICELLA ZOSTER VIRUS (VZV) | ModernaTX, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| EP-3364950-A1 | TROPICAL DISEASE VACCINES | ModernaTX, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| EP-3364981-A1 | HUMAN CYTOMEGALOVIRUS VACCINE | ModernaTX, Inc. (US) | 2018-08-29 | — | — | EP | disclosed |
| EP-3362461-A1 | MRNA CAP ANALOGS WITH MODIFIED PHOSPHATE LINKAGE | Modernatx, Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-3362460-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | Modernatx, Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| US-20180221494-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-08-09 | — | — | US | disclosed |
| WO-2018144082-A1 | RNA CANCER VACCINES | MODERNATX, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
| EP-2694660-B1 | EFFICIENT PROTEIN EXPRESSION IN VIVO USING MODIFIED RNA (MOD-RNA) | MASSACHUSETTS GEN HOSPITAL (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20180214579-A1 | POLYNUCLEOTIDE COMPOSITIONS CONTAINING AMINO ACIDS | MODERNA THERAPEUTICS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180216078-A1 | SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC, MODIFIED RNAS AND USES THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2018-08-02 | — | — | US | disclosed |
| EP-3353309-A1 | COMPOSITIONS AND METHODS FOR GENOME EDITING | Tarveda Therapeutics, Inc. (US) | 2018-08-01 | — | — | EP | disclosed |
| US-10036017-B2 | Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180208927-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-07-26 | — | — | US | disclosed |
| WO-2018136620-A2 | ENDOSOMAL CLEAVABLE LINKERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| US-10023626-B2 | Polynucleotides encoding immune modulating polypeptides | MODERNATX, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10022435-B2 | Nucleic acid vaccines | MODERNATX, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10011834-B2 | Methods and compositions for the specific inhibition of HIF-1α by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| WO-2018111967-A1 | RNA AFFINITY PURIFICATION | MODERNATX, INC. (US) | 2018-06-21 | — | — | WO | disclosed |
| US-10000756-B2 | Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-06-19 | — | — | US | disclosed |
| US-20180162893-A1 | UTILITY OF NEMATODE SMALL MOLECULES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-14 | — | — | US | disclosed |
| EP-3328394-A1 | CONCATEMERIC PEPTIDE EPITOPE RNAS | ModernaTX, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| US-20180147298-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148726-A1 | RNAi Inhibition of Alpha-ENaC Expression | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2018-05-31 | — | — | US | disclosed |
| EP-3324979-A2 | INFECTIOUS DISEASE VACCINES | ModernaTX, Inc. (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-3324980-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | Alnylam Pharmaceuticals, Inc. (US) | 2018-05-30 | — | — | EP | disclosed |
| US-20180141992-A1 | CELLS LACKING B2M SURFACE EXPRESSION AND METHODS FOR ALLOGENEIC ADMINISTRATION OF SUCH CELLS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180140625-A1 | PRODUCTION OF STABLE NON-POLYADENYLATED RNAS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-05-24 | — | — | US | disclosed |
| US-20180126003-A1 | NEW TARGETS FOR RNA THERAPEUTICS | CureVac SE (DE) | 2018-05-10 | — | — | US | disclosed |
| WO-2018075980-A1 | HUMAN CYTOMEGALOVIRUS VACCINE | MODERNATX, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| US-9944690-B2 | Methods for controlling T cell proliferation | BELLICUM PHARMACEUTICALS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9932572-B2 | Modified Caspase polypeptides and uses thereof | BELLICUM PHARMACEUTICALS, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20180085391-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPHTHALMIC DISEASES AND CONDITIONS | MODERNA THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9925277-B2 | Polynucleotide compositions containing amino acids | MODERNATX, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9913882-B2 | Methods for inducing partial apoptosis using caspase polypeptides | BELLICUM PHARMACEUTICALS, INC. (US) | 2018-03-13 | — | — | US | disclosed |
| US-9914927-B2 | RNAi inhibition of alpha-ENaC expression | Arrowhead Pharmaceuticals, Inc. (US) | 2018-03-13 | — | — | US | disclosed |
| US-20180051277-A1 | PROTECTION OF BARCODES DURING DNA AMPLIFICATION USING MOLECULAR HAIRPINS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2018-02-22 | — | — | US | disclosed |
| WO-2018035253-A1 | COMPOSITIONS AND METHODS FOR CARDIAC REPAIR | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2018-02-22 | — | — | WO | disclosed |
| US-9895448-B2 | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-02-20 | — | — | US | disclosed |
| US-20180044680-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF KRAS BY ASYMMETRIC DOUBLE-STRANDED RNA | NOVO NORDISK A/S (DK) | 2018-02-15 | — | — | US | disclosed |
| US-20180028645-A1 | HUMAN CYTOMEGALOVIRUS RNA VACCINES | MODERNATX, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180028664-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | MODERNATX, INC. (US) | 2018-02-01 | — | — | US | disclosed |
| EP-3273976-A1 | MODIFIED T CELLS AND METHODS OF MAKING AND USING THE SAME | President and Fellows of Harvard College (US) | 2018-01-31 | — | — | EP | disclosed |
| US-9872900-B2 | Nucleic acid vaccines | MODERNATX, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| EP-3268014-A2 | T-CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF | Leiden University Medical Center (NL) | 2018-01-17 | — | — | EP | disclosed |
| EP-2915815-B1 | NEW MODIFIED NUCLEIC ACID | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-17 | — | — | EP | disclosed |
| US-9868754-B2 | Utility of nematode small molecules | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-01-16 | — | — | US | disclosed |
| US-20180008694-A1 | CHIKAGUNYA VIRUS RNA VACCINES | MODERNATX, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| EP-2321414-B1 | ENHANCEMENT OF SIRNA SILENCING ACTIVITY USING UNIVERSAL BASES OR MISMATCHES IN THE SENSE STRAND | ALNYLAM PHARMACEUTICALS INC (US) | 2018-01-10 | — | — | EP | disclosed |
| US-20170369872-A1 | REVERSIR TM COMPOUNDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-9850486-B2 | Methods and compositions for the specific inhibition of CKAP5 by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170355958-A1 | MODULATION OF SH2B3 TO IMPROVE RED BLOOD CELL PRODUCTION FROM STEM CELLS AND/OR PROGENITOR CELLS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170356055-A1 | MIRNA EXPRESSION SIGNATURE IN THE CLASSIFICATION OF THYROID TUMORS | GENOPTIX, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170348415-A1 | TOLEROGENIC COMPOSITIONS AND METHODS | MODERNATX, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170340725-A1 | COMBINATION PIV3/HMPV RNA VACCINES | MODERNATX, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340724-A1 | ZIKA VIRUS RNA VACCINES | MODERNATX, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-9828606-B2 | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| WO-2017201333-A1 | POLYNUCLEOTIDES ENCODING LIPOPROTEIN LIPASE FOR THE TREATMENT OF HYPERLIPIDEMIA | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201325-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201349-A1 | POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201346-A1 | POLYNUCLEOTIDES ENCODING PORPHOBILINOGEN DEAMINASE FOR THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201352-A1 | MRNA COMBINATION THERAPY FOR THE TREATMENT OF CANCER | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201332-A1 | POLYNUCLEOTIDES ENCODING ACYL-COA DEHYDROGENASE, VERY LONG-CHAIN FOR THE TREATMENT OF VERY LONG-CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201347-A1 | POLYNUCLEOTIDES ENCODING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR FOR THE TREATMENT OF CYSTIC FIBROSIS | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201348-A1 | POLYNUCLEOTIDES ENCODING GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE FOR THE TREATMENT OF GALACTOSEMIA TYPE 1 | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201317-A1 | POLYRIBONUCLEOTIDES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201328-A1 | POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201342-A1 | POLYNUCLEOTIDES ENCODING JAGGED1 FOR THE TREATMENT OF ALAGILLE SYNDROME | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017201350-A1 | POLYNUCLEOTIDES ENCODING INTERLEUKIN-12 (IL12) AND USES THEREOF | MODERNATX, INC. (US) | 2017-11-23 | — | — | WO | disclosed |
| US-9822370-B2 | Method of making a deletion in a target sequence in isolated primary cells using Cas9 and two guide RNAs | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170327846-A1 | METHODS AND COMPOSITIONS TO INCREASE SOMATIC CELL NUCLEAR TRANSFER (SCNT) EFFICIENCY BY REMOVING HISTONE H3-LYSINE TRIMETHYLATION | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-11-16 | — | — | US | disclosed |
| WO-2017193087-A1 | LIPOSOMAL SPHERICAL NUCLEIC ACID (SNA) CONSTRUCTS PRSENTING ANTISENSE OLIGONUCLEOTIDES(ASO) FOR SPECIFIC KNOCKDOWN OF INTERLEUKIN 17 RECEPTOR MRNA | EXICURE, INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| US-9809819-B2 | Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9803177-B2 | Induced pluripotent stem cells with synthetic modified RNAs | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170305956-A1 | Ligand-Modified Double-Stranded Nucleic Acids | NOVO NORDISK A/S (DK) | 2017-10-26 | — | — | US | disclosed |
| US-20170306333-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GLYCOLATE OXIDASE (HAO1) BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170306332-A1 | THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR | DICERNA PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| WO-2017184427-A1 | TOPICAL ADMINISTRATION OF THERAPEUTIC AGENTS AND OLIGONUCLEOTIDE FORMULATIONS | EXICURE, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20170306331-A1 | ANTI-TNF COMPOUNDS | FLASHPOINT THERAPEUTICS, INC. | 2017-10-26 | — | — | US | disclosed |
| EP-3234144-A2 | METHODS FOR CONTROLLED ELIMINATION OF THERAPEUTIC CELLS | Bellicum Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-3234132-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | Dicerna Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-3234141-A1 | REVERSIR TM COMPOUNDS | Alnylam Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-3234145-A2 | METHODS FOR CONTROLLED ACTIVATION OR ELIMINATION OF THERAPEUTIC CELLS | Bellicum Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2017180587-A2 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. (US) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017180917-A2 | LIPID COMPOSITIONS AND THEIR USES FOR INTRATUMORAL POLYNUCLEOTIDE DELIVERY | MODERNATX, INC. (US) | 2017-10-19 | — | — | WO | disclosed |
| EP-3224350-A1 | MODULATION OF SH2B3 TO IMPROVE RED BLOOD CELL PRODUCTION FROM STEM CELLS AND/OR PROGENITOR CELLS | Children's Medical Center Corporation (US) | 2017-10-04 | — | — | EP | disclosed |
| US-20170275618-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF MYC BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS INC (US) | 2017-09-28 | — | — | US | disclosed |
| EP-3215522-A1 | T CELL RECEPTORS DIRECTED AGAINST BOB1 AND USES THEREOF | Leiden University Medical Center (NL) | 2017-09-13 | — | — | EP | disclosed |
| EP-3204499-A1 | ANTI-TNF COMPOUNDS | Exicure, Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-2379083-B1 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | DICERNA PHARMACEUTICALS INC (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-3204497-A1 | THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR | Dicerna Pharmaceuticals, Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| US-9732347-B2 | Methods and compositions for the specific inhibition of androgen receptor by double-stranded RNA | DICERNA PHARMACEUTICALS, INC (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170226507-A1 | COORDINATE CONTROL OF PATHOGENIC SIGNALING BY THE MIR-130/301 FAMILY IN PULMONARY HYPERTENSION AND FIBROPROLIFERATIVE DISEASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-9725479-B2 | 5′-end derivatives | IONIS PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725474-B2 | Modified nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| EP-3199165-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF KRAS BY ASYMMETRIC DOUBLE-STRANDED RNA | Dicerna Pharmaceuticals, Inc. (US) | 2017-08-02 | — | — | EP | disclosed |
| US-9717749-B2 | Production of stable non-polyadenylated RNAs | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-08-01 | — | — | US | disclosed |
| WO-2017127750-A1 | MESSENGER RIBONUCLEIC ACIDS FOR THE PRODUCTION OF INTRACELLULAR BINDING POLYPEPTIDES AND METHODS OF USE THEREOF | MODERNATX, INC. (US) | 2017-07-27 | — | — | WO | disclosed |
| US-20170210788-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF INTRABODIES | MODERNATX, INC. | 2017-07-27 | — | — | US | disclosed |
| EP-3194581-A2 | METHODS AND COMPOSITIONS TO INCREASE SOMATIC CELL NUCLEAR TRANSFER (SCNT) EFFICIENCY BY REMOVING HISTONE H3-LYSINE TRIMETHYLATION | Children's Medical Center Corporation (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20170204411-A1 | METHODS AND COMPOSITIONS FOR TREATING INSECTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170204422-A1 | CIRCULAR POLYNUCLEOTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2017-07-20 | — | — | US | disclosed |
| US-20170204152-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-9708605-B2 | Methods and compositions for the specific inhibition of MCL1 by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708667-B2 | MiRNA expression signature in the classification of thyroid tumors | ROSETTA GENOMICS, LTD. (IL) | 2017-07-18 | — | — | US | disclosed |
| WO-2017120612-A1 | THERAPEUTIC MRNAS ENCODING ANTI CTLA-4 ANTIBODIES | MODERNATX, INC. (US) | 2017-07-13 | — | — | WO | disclosed |
| EP-3189148-A1 | COSTIMULATION OF CHIMERIC ANTIGEN RECEPTORS BY MYD88 AND CD40 POLYPEPTIDES | Bellicum Pharmaceuticals, Inc. (US) | 2017-07-12 | — | — | EP | disclosed |
| EP-3188749-A1 | TOLEROGENIC COMPOSITIONS AND METHODS | Moderna Therapeutics, Inc. (US) | 2017-07-12 | — | — | EP | disclosed |
| US-9701966-B2 | Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20170191120-A1 | NUCLEIC ACID AMPLIFICATION AND USE THEREOF | MORRISON TOM B (US) | 2017-07-06 | — | — | US | disclosed |
| WO-2017112943-A1 | METHODS OF USING OX40 LIGAND ENCODING POLYNUCLEOTIDES | MODERNATX, INC. (US) | 2017-06-29 | — | — | WO | disclosed |
| US-20170183723-A1 | NUCLEIC ACID AMPLIFICATION AND USE THEREOF | ACCUGENOMICS INC (US) | 2017-06-29 | — | — | US | disclosed |
| WO-2017106185-A2 | DUAL CONTROLS FOR THERAPEUTIC CELL ACTIVATION OR ELIMINATION | BELLICUM PHARMACEUTICALS, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017106799-A1 | POLYNUCLEOTIDES ENCODING METHYLMALONYL-CoA MUTASE | MODERNATX, INC. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170173128-A1 | TARGETED ADAPTIVE VACCINES | MODERNA THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| WO-2017099823-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-06-15 | — | — | WO | disclosed |
| US-20170166877-A1 | DUAL CONTROLS FOR THERAPEUTIC CELL ACTIVATION OR ELIMINATION | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-06-15 | — | — | US | disclosed |
| CN-103841827-B | Small molecule compounds for controlling plant-and insect-pathogenic nematodes | 加利福尼亚技术学院 | 2017-06-09 | — | — | CN | disclosed |
| US-9670488-B2 | Methods and compositions for the specific inhibition of met by double stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| EP-2591105-B1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF BETA-CATENIN BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS INC (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-3171895-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF INTRABODIES | Modernatx, Inc. (US) | 2017-05-31 | — | — | EP | disclosed |
| US-20170145420-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-05-25 | — | — | US | disclosed |
| EP-3169335-A2 | CIRCULAR POLYNUCLEOTIDES | Moderna Therapeutics, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| US-20170130221-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STANDED RNA | NOVO NORDISK A/S (DK) | 2017-05-11 | — | — | US | disclosed |
| WO-2017070613-A1 | HUMAN CYTOMEGALOVIRUS VACCINE | MODERNATX, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070601-A1 | NUCLEIC ACID VACCINES FOR VARICELLA ZOSTER VIRUS (VZV) | MODERNATX, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070623-A1 | HERPES SIMPLEX VIRUS VACCINE | MODERNATX, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070622-A1 | RESPIRATORY SYNCYTIAL VIRUS VACCINE | MODERNATX, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070618-A1 | CANCER VACCINES | MODERNATX, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070624-A1 | TROPICAL DISEASE VACCINES | MODERNATX, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070616-A2 | SEXUALLY TRANSMITTED DISEASE VACCINES | MODERNATX, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017070620-A2 | BROAD SPECTRUM INFLUENZA VIRUS VACCINE | MODERNATX, INC. (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017066793-A1 | MRNA CAP ANALOGS AND METHODS OF MRNA CAPPING | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066791-A1 | SUGAR SUBSTITUTED MRNA CAP ANALOGS | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066797-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| US-20170107511-A1 | OLIGONUCLEOTIDE END CAPS | BANK OF AMERICA, N.A. | 2017-04-20 | — | — | US | disclosed |
| WO-2017066781-A1 | MRNA CAP ANALOGS WITH MODIFIED PHOSPHATE LINKAGE | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066782-A1 | HYDROPHOBIC MRNA CAP ANALOGS | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066789-A1 | MRNA CAP ANALOGS WITH MODIFIED SUGAR | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017062706-A1 | METHODS AND COMPOSITIONS TO INCREASE HUMAN SOMATIC CELL NUCLEAR TRANSFER (SCNT) EFFICIENCY BY REMOVING HISTONE H3-LYSINE TRIMETHYLATION, AND DERIVATION OF HUMAN NT-ESC | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2017-04-13 | — | — | WO | disclosed |
| WO-2017053713-A1 | COMPOSITIONS AND METHODS FOR GENOME EDITING | TARVEDA THERAPEUTICS, INC. (US) | 2017-03-30 | — | — | WO | disclosed |
| WO-2017049074-A1 | POLYNUCLEOTIDE FORMULATIONS FOR USE IN THE TREATMENT OF RENAL DISEASES | MODERNA THERAPEUTICS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| EP-3143162-A1 | MIRNA EXPRESSION SIGNATURE IN THE CLASSIFICATION OF THYROID TUMORS | Rosetta Genomics Ltd. (IL) | 2017-03-22 | — | — | EP | disclosed |
| EP-2756845-B1 | Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA | DICERNA PHARMACEUTICALS INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9593141-B2 | Lin28/let-7 crystal structures, purification protocols, and molecular probes suitable for screening assays and therapeutics | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-14 | — | — | US | disclosed |
| US-9562228-B2 | Methods and compositions for the specific inhibition of MYC by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2017-02-07 | — | — | US | disclosed |
| WO-2017020026-A1 | CONCATEMERIC PEPTIDE EPITOPES RNAS | MODERNATX, INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| WO-2017019935-A1 | MULTIMERIC MRNA | MODERNATX, INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| WO-2017015109-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-01-26 | — | — | WO | disclosed |
| WO-2017015457-A1 | EBOLA VACCINE | MODERNATX, INC. (US) | 2017-01-26 | — | — | WO | disclosed |
| US-20170015987-A1 | MODIFIED CASPASE POLYPEPTIDES AND USES THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2017-01-19 | — | — | US | disclosed |
| US-20170016076-A1 | MIRNA EXPRESSION SIGNATURE IN THE CLASSIFICATION OF THYROID TUMORS | GENOPTIX, INC. | 2017-01-19 | — | — | US | disclosed |
| US-20170007595-A1 | NSD3 INHIBITORS FOR TREATMENT OF CANCERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-01-12 | — | — | US | disclosed |
| EP-3114217-A1 | CASPASE POLYPEPTIDES HAVING MODIFIED ACTIVITY AND USES THEREOF | Bellicum Pharmaceuticals, Inc. (US) | 2017-01-11 | — | — | EP | disclosed |
| US-9534008-B2 | Small molecule compounds that control plant- and insect-pathogenic nematodes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160376599-A1 | RNAi Inhibition of Alpha-ENaC Expression | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2016-12-29 | — | — | US | disclosed |
| US-20160367687-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-12-22 | — | — | US | disclosed |
| EP-3104866-A1 | METHODS FOR ACTIVATING T CELLS USING AN INDUCIBLE CHIMERIC POLYPEPTIDE | Bellicum Pharmaceuticals, Inc. (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9512164-B2 | Oligonucleotide end caps | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20160348073-A1 | MODIFIED T CELLS AND METHODS OF MAKING AND USING THE SAME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-12-01 | — | — | US | disclosed |
| US-20160348110-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2016-12-01 | — | — | US | disclosed |
| WO-2016183009-A2 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ANTITHROMBIN 3 (AT3) BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| US-20160331828-A1 | NUCLEIC ACID VACCINES | MODERNA THERAPEUTICS, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-9487551-B2 | Small molecule compounds that control mammal-pathogenic nematodes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2016-11-08 | — | — | US | disclosed |
| US-20160317647-A1 | NUCLEIC ACID VACCINES | MODERNA THERAPEUTICS, INC. (US) | 2016-11-03 | — | — | US | disclosed |
| EP-1913011-B1 | OLIGONUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS INC (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-3087184-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GLYCOLATE OXIDASE (HAO1) BY DOUBLE-STRANDED RNA | Dicerna Pharmaceuticals Inc. (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-3084446-A1 | HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA | Acetylon Pharmaceuticals, Inc. (US) | 2016-10-26 | — | — | EP | disclosed |
| US-9476052-B2 | RNAi inhibition of alpha-ENaC expression | Arrowhead Pharmaceuticals, Inc. (US) | 2016-10-25 | — | — | US | disclosed |
| US-20160304870-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF TRANSTHYRETIN (TTR) BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. | 2016-10-20 | — | — | US | disclosed |
| EP-3077511-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF TRANSTHYRETIN (TTR) BY DOUBLE-STRANDED RNA | Dicerna Pharmaceuticals Inc. (US) | 2016-10-12 | — | — | EP | disclosed |
| WO-2016160721-A1 | MODIFIED T CELLS AND METHODS OF MAKING AND USING THE SAME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-10-06 | — | — | WO | disclosed |
| US-9458457-B2 | Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458464-B2 | Treatment of neuropathic pain | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20160281091-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF MYC BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. | 2016-09-29 | — | — | US | disclosed |
| EP-3072961-A1 | SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC, MODIFIED RNAS AND USES THEREOF | Children's Medical Center Corporation (US) | 2016-09-28 | — | — | EP | disclosed |
| US-9453043-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9445596-B2 | Small molecule compounds for the control of nematodes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2016-09-20 | — | — | US | disclosed |
| WO-2016142783-A2 | T-CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF | LEIDEN UNIVERSITY MEDICAL CENTER (NL) | 2016-09-15 | — | — | WO | disclosed |
| US-20160263155-A1 | T CELL RECEPTORS DIRECTED AGAINST THE PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA AND USES THEREOF | LEIDEN UNIVERSITY MEDICAL CENTER (NL) | 2016-09-15 | — | — | US | disclosed |
| US-9434935-B2 | Modified caspase polypeptides and uses thereof | BELLICUM PHARMACEUTICALS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| WO-2016138080-A1 | PROTECTION OF BARCODES DURING DNA AMPLIFICATION USING MOLECULAR HAIRPINS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2016-09-01 | — | — | WO | disclosed |
| US-9428752-B2 | Methods and compositions for the specific inhibition of beta-catenin by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20160244501-A1 | Polynucleotides Encoding Low Density Lipoprotein Receptor | MODERNA THERAPEUTICS, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160244502-A1 | POLYNUCLEOTIDES ENCODING IMMUNE MODULATING POLYPEPTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2016-08-25 | — | — | US | disclosed |
| US-20160243221-A1 | COMPOSITIONS AND METHODS FOR TOLERIZING CELLULAR SYSTEMS | MODERNA THERAPEUTICS, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| US-20160243259-A1 | POLYNUCLEOTIDE COMPOSITIONS CONTAINING AMINO ACIDS | ARES CAPITAL CORPORATION, AS AGENT | 2016-08-25 | — | — | US | disclosed |
| US-20160237438-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF COMPLEMENT COMPONENT 5(C5) BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160220647-A1 | PROTEINS FOR TARGETING NEURONAL NITRIC OXIDE SYNTHASE TO MUSCLE SARCOLEMMA AND RELATED METHODS OF USE | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2016-08-04 | — | — | US | disclosed |
| US-20160215042-A1 | METHODS FOR MODULATING IMMUNE RESPONSES DURING CHRONIC IMMUNE CONDITIONS BY TARGETING METALLOTHIONEINS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-07-28 | — | — | US | disclosed |
| US-9393292-B2 | Methods for inducing selective apoptosis | BAYLOR COLLEGE OF MEDICINE (US) | 2016-07-19 | — | — | US | disclosed |
| EP-3041934-A1 | CHIMERIC POLYNUCLEOTIDES | Moderna Therapeutics, Inc. (US) | 2016-07-13 | — | — | EP | disclosed |
| US-9388412-B2 | Inhibitors of microRNAs that regulate production of atrial natriuretic peptide (ANP) as therapeutics and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2016-07-12 | — | — | US | disclosed |
| US-20160194625-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNATX, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160186176-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF BETA-CATENIN BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160186263-A1 | USING PLEXIN-A4 AS A BIOMARKER AND THERAPEUTIC TARGET FOR ALZHEIMER'S DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-30 | — | — | US | disclosed |
| EP-3037538-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF BETA-CATENIN BY DOUBLE-STRANDED RNA | Dicerna Pharmaceuticals, Inc. (US) | 2016-06-29 | — | — | EP | disclosed |
| WO-2016100716-A1 | REVERSIRTM COMPOUNDS | JADHAV VASANT (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160177303-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF HIF-1a BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. | 2016-06-23 | — | — | US | disclosed |
| WO-2016100241-A2 | METHODS FOR CONTROLLED ACTIVATION OR ELIMINATION OF THERAPEUTIC CELLS | BELLICUM PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016100236-A2 | METHODS FOR CONTROLLED ELIMINATION OF THERAPEUTIC CELLS | BELLICUM PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016100401-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | DICERNA PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160175359-A1 | METHODS FOR CONTROLLED ACTIVATION OR ELIMINATION OF THERAPEUTIC CELLS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2016-06-23 | — | — | US | disclosed |
| US-20160166613-A1 | METHODS FOR CONTROLLED ELIMINATION OF THERAPEUTIC CELLS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2016-06-16 | — | — | US | disclosed |
| US-9365850-B2 | Methods and compositions for the specific inhibition of MYC by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160151465-A1 | METHODS FOR INDUCING PARTIAL APOPTOSIS USING CASPASE POLYPEPTIDES | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2016-06-02 | — | — | US | disclosed |
| WO-2016085934-A1 | MODULATION OF SH2B3 TO IMPROVE RED BLOOD CELL PRODUCTION FROM STEM CELLS AND/OR PROGENITOR CELLS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2016-06-02 | — | — | WO | disclosed |
| US-9345780-B2 | Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic components | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-05-24 | — | — | US | disclosed |
| WO-2016077574-A1 | INHIBITORS OF MICRORNAs miR-155, miR-103, miR-105 and miR-107 THAT REGULATE PRODUCTION OF ATRIAL NATRIURETIC PEPTIDE (ANP) AS THERAPEUTICS AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2016-05-19 | — | — | WO | disclosed |
| EP-3019595-A2 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/CAS SYSTEMS | President and Fellows of Harvard College (US) | 2016-05-18 | — | — | EP | disclosed |
| US-20160129094-A1 | T CELL RECEPTORS DIRECTED AGAINST BOB1 AND USES THEREOF | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2016-05-12 | — | — | US | disclosed |
| WO-2016071758-A1 | T CELL RECEPTORS DIRECTED AGAINST BOB1 AND USES THEREOF | LEIDEN UNIVERSITY MEDICAL CENTER (NL) | 2016-05-12 | — | — | WO | disclosed |
| EP-3017047-A2 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA | Dicerna Pharmaceuticals Inc. (US) | 2016-05-11 | — | — | EP | disclosed |
| US-9320798-B2 | Lipid delivery formulations | DICERNA PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| WO-2016057835-A2 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057932-A1 | THERAPEUTIC INHIBITION OF LACTATE DEHYDROGENASE AND AGENTS THEREFOR | DICERNA PHARMACEUTICALS, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057549-A1 | ANTI-TNF COMPOUNDS | AURASENSE THERAPEUTICS, LLC (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057821-A2 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/CAS SYSTEMS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-04-14 | — | — | WO | disclosed |
| EP-3004329-A2 | METHODS FOR INDUCING PARTIAL APOPTOSIS USING CASPASE POLYPEPTIDES | Bellicum Pharmaceuticals, Inc. (US) | 2016-04-13 | — | — | EP | disclosed |
| WO-2016044271-A2 | METHODS AND COMPOSITIONS TO INCREASE SOMATIC CELL NUCLEAR TRANSFER (SCNT) EFFICIENCY BY REMOVING HISTONE H3-LYSINE TRIMETHYLATION | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016036902-A1 | TOLEROGENIC COMPOSITIONS AND METHODS | MODERNA THERAPEUTICS, INC. (US) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016036746-A1 | COSTIMULATION OF CHIMERIC ANTIGEN RECEPTORS BY MYD88 AND CD40 POLYPEPTIDES | BELLICUM PHARMACEUTICALS, INC. (US) | 2016-03-10 | — | — | WO | disclosed |
| US-20160058857-A1 | COSTIMULATION OF CHIMERIC ANTIGEN RECEPTORS BY MYD88 AND CD40 POLYPEPTIDES | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2016-03-03 | — | — | US | disclosed |
| US-20160053263-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF BETA-CATENIN BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. | 2016-02-25 | — | — | US | disclosed |
| US-20160046700-A1 | METHODS FOR ACTIVATING T CELLS USING AN INDUCIBLE CHIMERIC POLYPEPTIDE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2016-02-18 | — | — | US | disclosed |
| US-20160037741-A1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. | 2016-02-11 | — | — | US | disclosed |
| EP-2981617-A2 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/CAS SYSTEMS | President and Fellows of Harvard College (US) | 2016-02-10 | — | — | EP | disclosed |
| US-20160032317-A1 | COMPOSITIONS AND METHODS FOR REPROGRAMMING HEMATOPOIETIC STEM CELL LINEAGES | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2016-02-04 | — | — | US | disclosed |
| WO-2016014846-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF INTRABODIES | MODERNA THERAPEUTICS, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| US-9243244-B2 | Methods and compositions for the specific inhibition of beta-catenin by double stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2016-01-26 | — | — | US | disclosed |
| WO-2016011222-A2 | CIRCULAR POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| US-20160016983-A1 | New Modified Nucleic Acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-21 | — | — | US | disclosed |
| EP-2970881-A2 | COMPOSITIONS AND METHODS FOR REPROGRAMMING HEMATOPOIETIC STEM CELL LINEAGES | Children's Medical Center Corporation (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2967081-A2 | MODIFIED CASPASE POLYPEPTIDES AND USES THEREOF | Bellicum Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968502-A2 | METHODS FOR CONTROLLING T CELL PROLIFERATION | Bellicum Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2967052-A2 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS | Boyce Thompson Institute for Plant Research Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20160008421-A1 | METHOD OF ALTERING VASCULAR PERMEABILITY AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-14 | — | — | US | disclosed |
| US-20150368652-A1 | TREATMENT OF NEUROPATHIC PAIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-24 | — | — | US | disclosed |
| US-20150366954-A1 | METHODS FOR INDUCING SELECTIVE APOPTOSIS | BAYLOR COLLEGE OF MEDICINE | 2015-12-24 | — | — | US | disclosed |
| US-9206420-B2 | Methods and compositions for the specific inhibition of HIF-1α by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9200284-B2 | Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150328292-A1 | CASPASE POLYPEPTIDES HAVING MODIFIED ACTIVITY AND USES THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-11-19 | — | — | US | disclosed |
| WO-2015175660-A1 | MIRNA EXPRESSION SIGNATURE IN THE CLASSIFICATION OF THYROID TUMORS | ROSETTA GENOMICS, LTD. (IL) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015171641-A1 | COORDINATE CONTROL OF PATHOGENIC SIGNALING BY THE MIR-130/301 FAMILY IN PULMONARY HYPERTENSION AND FIBROPROLIFERATIVE DISEASES | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| US-20150315583-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF CKAP5 BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| US-20150315574-A1 | PRODUCTION OF STABLE NON-POLYADENYLATED RNAS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-11-05 | — | — | US | disclosed |
| EP-2931746-A2 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF CKAP5 BY DOUBLE-STRANDED RNA | Dicerna Pharmaceuticals Inc. (US) | 2015-10-21 | — | — | EP | disclosed |
| US-20150291999-A1 | NUCLEIC ACID AMPLIFICATION AND USE THEREOF | ACCUGENOMICS INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20150284726-A1 | RNAi Inhibition of A1pha-ENaC Expression | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2015-10-08 | — | — | US | disclosed |
| US-20150267260-A1 | NUCLEIC ACID AMPLIFICATION AND USE THEREOF | ACCUGENOMICS INC (US) | 2015-09-24 | — | — | US | disclosed |
| EP-2348017-B1 | AROMATIC AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | MITSUI CHEMICALS INC (JP) | 2015-09-23 | — | — | EP | disclosed |
| WO-2015134877-A1 | CASPASE POLYPEPTIDES HAVING MODIFIED ACTIVITY AND USES THEREOF | BELLICUM PHARMACEUTICALS, INC. (US) | 2015-09-11 | — | — | WO | disclosed |
| EP-2915815-A1 | NEW MODIFIED NUCLEIC ACID | Takeda Pharmaceutical Company Limited (JP) | 2015-09-09 | — | — | EP | disclosed |
| US-20150240234-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF MYC BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| EP-2909321-A1 | PRODUCTION OF STABLE NON-POLYADENYLATED RNAS | Massachusetts Institute of Technology (US) | 2015-08-26 | — | — | EP | disclosed |
| WO-2015123527-A1 | METHODS FOR ACTIVATING T CELLS USING AN INDUCIBLE CHIMERIC POLYPEPTIDE | BELLICUM PHARMACEUTICALS, INC. (US) | 2015-08-20 | — | — | WO | disclosed |
| US-9102938-B2 | 2′ and 5′ modified monomers and oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | BANK OF AMERICA, N.A. | 2015-07-30 | — | — | US | disclosed |
| WO-2015112809-A2 | NSD3 INHIBITORS FOR TREATMENT OF CANCERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| US-9089520-B2 | Methods for inducing selective apoptosis | BAYLOR COLLEGE OF MEDICINE (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2895609-A1 | METHODS AND COMPOSTIONS FOR THE SPECIFIC INHIBITION OF MYC BY DOUBLE-STRANDED RNA | Dicerna Pharmaceuticals, Inc. (US) | 2015-07-22 | — | — | EP | disclosed |
| US-20150197756-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ANDROGEN RECEPTOR BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. | 2015-07-16 | — | — | US | disclosed |
| US-9074212-B2 | RNAi inhibition of alpha-ENaC expression | ARROWHEAD RESEARCH CORPORATION (US) | 2015-07-07 | — | — | US | disclosed |
| WO-2015100436-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GLYCOLATE OXIDASE (HAO1) BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2015-07-02 | — | — | WO | disclosed |
| US-20150184160-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GLYCOLATE OXIDASE (HAO1) BY DOUBLE-STRANDED RNA | NOVO NORDISK A/S (DK) | 2015-07-02 | — | — | US | disclosed |
| WO-2015095632-A1 | HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150176076-A1 | HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150176013-A1 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | THE CHILDREN'S MEDICAL CENTER CORPORATION | 2015-06-25 | — | — | US | disclosed |
| WO-2015085158-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF TRANSTHYRETIN (TTR) BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2015-06-11 | — | — | WO | disclosed |
| US-20150152436-A1 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-04 | — | — | US | disclosed |
| US-20150132321-A1 | METHODS OF MODULATING ANGIOGENESIS VIA TRPV4 | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2015-05-14 | — | — | US | disclosed |
| US-20150133521-A1 | INHIBITORS OF MICRORNAs THAT REGULATE PRODUCTION OF ATRIAL NATRIURETIC PEPTIDE (ANP) AS THERAPEUTICS AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION | 2015-05-14 | — | — | US | disclosed |
| US-20150111954-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-23 | — | — | US | disclosed |
| EP-2855704-A1 | NUCLEIC ACID AMPLIFICATION AND USE THEREOF | Accugenomics, Inc. (US) | 2015-04-08 | — | — | EP | disclosed |
| US-20150080457-A1 | 5' PHOSPHATE MIMICS | BANK OF AMERICA, N.A. | 2015-03-19 | — | — | US | disclosed |
| WO-2015035364-A1 | PROTEINS FOR TARGETING NEURONAL NITRIC OXIDE SYNTHASE TO MUSCLE SARCOLEMMA AND RELATED METHODS OF USE | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2015-03-12 | — | — | WO | disclosed |
| US-20150071889-A1 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/Cas SYSTEMS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-03-12 | — | — | US | disclosed |
| WO-2015034928-A1 | CHIMERIC POLYNUCLEOTIDES | MODERNA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | WO | disclosed |
| US-8975389-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20150065555-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF MCL1 BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150057337-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF KRAS BY ASYMMETRIC DOUBLE-STRANDED RNA | NOVO NORDISK A/S (DK) | 2015-02-26 | — | — | US | disclosed |
| US-20150038554-A1 | Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression | NOVO NORDISK A/S (DK) | 2015-02-05 | — | — | US | disclosed |
| US-20150038555-A1 | Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression | NOVO NORDISK A/S (DK) | 2015-02-05 | — | — | US | disclosed |
| WO-2015006498-A2 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/CAS SYSTEMS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-01-15 | — | — | WO | disclosed |
| US-20150011614-A1 | METHODS AND COMPOSITIONS FOR TREATING INSECTS | ALNYLAM PHARMACEUTICALS, INC. | 2015-01-08 | — | — | US | disclosed |
| US-20150011607-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA | NOVO NORDISK A/S (DK) | 2015-01-08 | — | — | US | disclosed |
| WO-2015003113-A2 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ALPHA-1 ANTITRYPSIN BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | WO | disclosed |
| US-8927513-B2 | 5′ phosphate mimics | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927705-B2 | Single stranded extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927515-B2 | Methods and compositions for the specific inhibition of androgen receptor by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20140364386-A1 | Small Molecule Compounds That Control Plant- and Insect-Pathogenic Nematodes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-12-11 | — | — | US | disclosed |
| WO-2014197638-A2 | METHODS FOR INDUCING PARTIAL APOPTOSIS USING CASPASE POLYPEPTIDES | BELLICUM PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | WO | disclosed |
| US-20140350074-A1 | Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression | NOVO NORDISK A/S (DK) | 2014-11-27 | — | — | US | disclosed |
| EP-2418707-B1 | ORGANIC ELECTROLUMINESCENT ELEMENT AND MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT | IDEMITSU KOSAN CO (JP) | 2014-11-26 | — | — | EP | disclosed |
| WO-2014183023-A1 | USING PLEXIN-A4 AS A BIOMARKER AND THERAPEUTIC TARGET FOR ALZHEIMER'S DISEASE | TRUSTEES OF BOSTON UNIVERSITY (US) | 2014-11-13 | — | — | WO | disclosed |
| US-8883506-B2 | Kits comprising linear DNAs for sustained polypeptide expression using synthetic, modified RNAs | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2796563-A1 | Optimized degenerative muscle disease diagnostics and treatments | MedImmune, LLC (GB) | 2014-10-29 | — | — | EP | disclosed |
| WO-2014172606-A1 | METHODS FOR MODULATING IMMUNE RESPONSES DURING CHRONIC IMMUNE CONDITIONS BY TARGETING METALLOTHIONEINS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2014-10-23 | — | — | WO | disclosed |
| US-20140315983-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF MET BY DOUBLE STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-20140308746-A1 | SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC, MODIFIED RNAS AND USES THEREOF | IMMUNE DISEASE INSTITUTE, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20140303234-A1 | METHODS FOR THE MODULATION OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140303102-A1 | Small Molecule Compounds that Control Mammal-Pathogenic Nematodes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-10-09 | — | — | US | disclosed |
| WO-2014165825-A2 | THERAPEUTIC USES OF GENOME EDITING WITH CRISPR/CAS SYSTEMS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014164348-A2 | MODIFIED CASPASE POLYPEPTIDES AND USES THEREOF | BELLICUM PHARMACEUTICALS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140303360-A1 | Small Molecule Compounds for the Control of Nematodes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-10-09 | — | — | US | disclosed |
| WO-2014151960-A2 | METHODS FOR CONTROLLING T CELL PROLIFERATION | BELLICUM PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014153069-A2 | COMPOSITIONS AND METHODS FOR REPROGRAMMING HEMATOPOIETIC STEM CELL LINEAGES | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014153115-A2 | COMPOSITIONS AND METHODS FOR REPROGRAMMING HEMATOPOIETIC STEM CELL LINEAGES | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140288292-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF BETA-CATENIN BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. | 2014-09-25 | — | — | US | disclosed |
| US-20140286987-A1 | METHODS FOR CONTROLLING T CELL PROLIFERATION | BELLICUM PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| WO-2014152122-A2 | METHODS OF ALTERING VASCULAR PERMEABILITY AND USES THEREOF | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014145380-A2 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140256785-A1 | SITE SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2014-09-11 | — | — | US | disclosed |
| US-20140255360-A1 | MODIFIED CASPASE POLYPEPTIDES AND USES THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2014-09-11 | — | — | US | disclosed |
| US-8815825-B2 | Methods and compositions for the specific inhibition of beta-catenin by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| EP-2766501-A1 | NUCLEIC ACID AMPLIFICATION AND USE THEREOF | Accugenomics, Inc. (US) | 2014-08-20 | — | — | EP | disclosed |
| EP-2766379-A2 | SMALL MOLECULE COMPOUNDS FOR THE CONTROL OF NEMATODES | Boyce Thompson Institute For Plant Research (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20140227293-A1 | METHOD FOR CONTROLLING TUMOR GROWTH, ANGIOGENESIS AND METASTASIS USING IMMUNOGLOBULIN CONTAINING AND PROLINE RICH RECEPTOR-1 (IGPR-1) | TRUSTEES OF BOSTON UNIVERSITY (US) | 2014-08-14 | — | — | US | disclosed |
| US-8802438-B2 | Compositions, kits, and methods for making induced pluripotent stem cells using synthetic modified RNAs | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140221454-A1 | Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression | DICERNA PHARMACEUTICALS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| EP-2756845-A1 | Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA | Dicerna Pharmaceuticals, Inc. (US) | 2014-07-23 | — | — | EP | disclosed |
| WO-2014093746-A2 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF CKAP5 BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| EP-2741611-A2 | SMALL MOLECULE COMPOUNDS THAT CONTROL PLANT- AND INSECT-PATHOGENIC NEMATODES | The California Institute of Technology (US) | 2014-06-18 | — | — | EP | disclosed |
| EP-2741752-A2 | THE UTILITY OF NEMATODE SMALL MOLECULES | California Institute of Technology (US) | 2014-06-18 | — | — | EP | disclosed |
| US-20140155462-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITIONS OF EGFR BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140154783-A1 | BIOPROCESSING | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| CN-103841827-A | Small molecule compounds for controlling plant-and insect-pathogenic nematodes | CALIFORNIA INST OF TECHN | 2014-06-04 | — | — | CN | disclosed |
| US-8729046-B2 | MIR27B is a novel target for treatment of liver fibrosis | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2014-05-20 | — | — | US | disclosed |
| US-8722638-B2 | Methods for the modulation of angiogenesis | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-05-13 | — | — | US | disclosed |
| US-8716465-B2 | Kit for making induced pluripotent stem cells using modified RNAs | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2723349-A2 | MICRORNA-31 COMPOSITIONS AND METHODS FOR USE IN AUTOIMMUNE DISEASE | MedImmune, LLC (US) | 2014-04-30 | — | — | EP | disclosed |
| WO-2014062801-A1 | PRODUCTION OF STABLE NON-POLYADENYLATED RNAS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-04-24 | — | — | WO | disclosed |
| US-20140099666-A1 | COMPOSITIONS AND METHODS FOR ENHANCING PRODUCTION OF A BIOLOGICAL PRODUCT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-04-10 | — | — | US | disclosed |
| WO-2014043311-A1 | METHODS AND COMPOSTIONS FOR THE SPECIFIC INHIBITION OF MYC BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2014-03-20 | — | — | WO | disclosed |
| US-20140073687-A1 | EFFICIENT PROTEIN EXPRESSION IN VIVO USING MODIFIED RNA (MOD-RNA) | IMMUNE DISEASE INSTITUTE, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140045924-A1 | MELANOMA TREATMENTS | MEDIMMUNE, LLC (US) | 2014-02-13 | — | — | US | disclosed |
| EP-2694660-A1 | EFFICIENT PROTEIN EXPRESSION IN VIVO USING MODIFIED RNA (MOD-RNA) | The General Hospital Corporation (US) | 2014-02-12 | — | — | EP | disclosed |
| US-20140023647-A1 | METHOD FOR TREATING SOLID TUMORS | BELLICUM PHARMACEUTICALS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140004565-A1 | CELL-BASED BIOPROCESSING | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-01-02 | — | — | US | disclosed |
| US-20130338215-A1 | COMPOSITION AND METHOD FOR OLIGONUCLEOTIDE DELIVERY | CHILDREN'S MEDICAL CENTER CORPORATION | 2013-12-19 | — | — | US | disclosed |
| WO-2013187894-A1 | BISCARBAZOLE DERIVATIVE HOST MATERIALS AND RED EMITTER FOR OLED EMISSIVE REGION | UNIVERSAL DISPLAY CORPORATION (US) | 2013-12-19 | — | — | WO | disclosed |
| WO-2013188787-A1 | INHIBITORS OF MICRORNAs THAT REGULATE PRODUCTION OF ATRIAL NATRIURETIC PEPTIDE (ANP) AS THERAPEUTICS AND USES THEREOF | THE GENERAL HOSPITAL CORPORATION (US) | 2013-12-19 | — | — | WO | disclosed |
| US-20130323836-A1 | 5'-END DERIVATIVES | ISIS PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20130323834-A1 | METHODS FOR INDUCING SELECTIVE APOPTOSIS | BELLICUM PHARMACEUTICALS, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| EP-2669290-A1 | Nucleic Acid Chemical Modifications | Alnylam Pharmaceuticals Inc. (US) | 2013-12-04 | — | — | EP | disclosed |
| WO-2013177524-A1 | NUCLEIC ACID AMPLIFICATION AND USE THEREOF | ACCUGENOMICS, INC. (US) | 2013-11-28 | — | — | WO | disclosed |
| US-20130303593-A1 | Methods and Compositions for the Specific Inhibition of HIF-1a by Double-Stranded RNA | DICERNA PHARMACEUTICALS, INC. | 2013-11-14 | — | — | US | disclosed |
| EP-2658972-A2 | MELANOMA TREATMENTS | MedImmune, LLC (US) | 2013-11-06 | — | — | EP | disclosed |
| US-8575123-B2 | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2013-11-05 | — | — | US | disclosed |
| US-20130260460-A1 | CONFORMATIONALLY RESTRICTED DINUCLEOTIDE MONOMERS AND OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2013-10-03 | — | — | US | disclosed |
| WO-2013138668-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF MCL1 BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | WO | disclosed |
| US-20130236968-A1 | MULTIFUNCTIONAL COPOLYMERS FOR NUCLEIC ACID DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| EP-2224005-B1 | RNAi inhibition of alpha-ENaC expression | NOVARTIS AG (CH) | 2013-09-11 | — | — | EP | disclosed |
| US-20130225663-A1 | LIPID DELIVERY FORMULATIONS | DICERNA PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| EP-2403863-B1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8513207-B2 | Extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20130203836-A1 | 2' AND 5' MODIFIED MONOMERS AND OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130196410-A1 | COMPOSITIONS AND METHODS FOR MODIFYING THE GLYCOSYLATION PATTERN OF A POLYPEPTIDE | ALNYLAM PHARMACEUTICALS, INC (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130196434-A1 | ENHANCEMENT OF siRNA SILENCING ACTIVITY USING UNIVERSAL BASES OR MISMATCHES IN THE SENSE STRAND | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130189783-A1 | METHODS OF MODULATING ANGIOGENESIS VIA TRPV4 | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| EP-2223692-B1 | RNAi inhibition of alpha-ENaC expression | NOVARTIS AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| EP-2223693-B1 | RNAi inhibition of alpha-ENaC expression | NOVARTIS AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| EP-2223695-B1 | RNAi inhibition of alpha-ENaC expression | NOVARTIS AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| EP-2224004-B1 | RNAi inhibition of alpha-ENaC expression | NOVARTIS AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| EP-2223694-B1 | RNAi inhibition of alpha-ENaC expression | NOVARTIS AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-20130164851-A1 | GENE AMPLIFICATION AND TRANSFECTION METHODS AND REAGENTS RELATED THERETO | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130164329-A1 | CELL-BASED METHODS AND REAGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130150428-A1 | MIR27B IS A NOVEL TARGET FOR TREATMENT OF LIVER FIBROSIS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2013078199-A2 | METHODS FOR ENHANCED IN VIVO DELIVERY OF SYNTHETIC, MODIFIED RNAS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2013-05-30 | — | — | WO | disclosed |
| US-20130130378-A1 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131149-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ANDROGEN RECEPTOR BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130123342-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF KRAS BY ASYMMETRIC DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2013071079-A1 | LIN28/LET-7 CRYSTAL STRUCTURES, PURIFICATION PROTOCOLS, AND MOLECULAR PROBES SUITABLE FOR SCREENING ASSAYS AND THERAPEUTICS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013071047-A1 | COMPOSITIONS AND METHODS FOR IN VITRO TRANSCRIPTION OF RNA | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2013-05-16 | — | — | WO | disclosed |
| EP-2591104-A2 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ANDROGEN RECEPTOR BY DOUBLE-STRANDED RNA | Dicerna Pharmaceuticals, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2591105-A2 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF BETA-CATENIN BY DOUBLE-STRANDED RNA | Dicerna Pharmaceuticals, Inc. (US) | 2013-05-15 | — | — | EP | disclosed |
| WO-2013066721-A2 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF MET BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130109740-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF BETA-CATENIN BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130108646-A1 | OPTIMIZED DEGENERATIVE MUSCLE DISEASE DIAGNOSTICS AND TREATMENTS | MEDIMMUNE, LLC (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130096290-A1 | SINGLE STRANDED EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | DICERNA PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| WO-2013055789-A1 | NUCLEIC ACID AMPLIFICATION AND USE THEREOF | ACCUGENOMICS, INC. (US) | 2013-04-18 | — | — | WO | disclosed |
| EP-2566973-A2 | OPTIMIZED DEGENERATIVE MUSCLE DISEASE DIAGNOSTICS AND TREATMENTS | MedImmune, LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-8394779-B2 | Methods of modulating angiogenesis via TRPV4 | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2013-03-12 | — | — | US | disclosed |
| WO-2013032643-A2 | LIPIDS CAPABLE OF CONFORMATIONAL CHANGE AND THEIR USE IN FORMULATIONS TO DELIVER THERAPEUTIC AGENTS TO CELLS | DICERNA PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| EP-2295421-B1 | AROMATIC AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | IDEMITSU KOSAN CO (JP) | 2013-02-20 | — | — | EP | disclosed |
| EP-2558109-A2 | METHOD FOR TREATING SOLID TUMORS | Bellicum Pharmaceuticals Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| EP-2558571-A2 | SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC, MODIFIED RNAS AND USES THEREOF | Immune Disease Institute Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| US-20130041010-A1 | COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DSRNA CONTAINING MODIFIED NUCLEOTIDES | DICERNA PHARMACEUTICALS, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2013022997-A2 | SMALL MOLECULE COMPOUNDS THAT CONTROL PLANT- AND INSECT-PATHOGENIC NEMATODES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2013-02-14 | — | — | WO | disclosed |
| WO-2013022996-A2 | THE UTILITY OF NEMATODE SMALL MOLECULES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2013-02-14 | — | — | WO | disclosed |
| WO-2013023000-A2 | SMALL MOLECULE COMPOUNDS THAT CONTROL MAMMAL-PATHOGENIC NEMATODES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2013-02-14 | — | — | WO | disclosed |
| WO-2013022985-A2 | SMALL MOLECULE COMPOUNDS FOR THE CONTROL OF NEMATODES | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH (US) | 2013-02-14 | — | — | WO | disclosed |
| US-8372816-B2 | Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| WO-2013013013-A2 | COMPOSITIONS AND METHODS FOR PRODUCING MODIFIED GLYCOPROTEINS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013013019-A2 | LYSOSOMAL POLYPEPTIDES, METHODS OF MAKING AND USING | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| US-8349809-B2 | Single stranded extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| WO-2013003346-A2 | MICRORNA-31 COMPOSITIONS AND METHODS FOR USE IN AUTOIMMUNE DISEASE | MEDIMMUNE, LLC (US) | 2013-01-03 | — | — | WO | disclosed |
| WO-2013003697-A1 | METHOD FOR CONTROLLING TUMOR GROWTH, ANGIOGENESIS AND METASTASIS USING IMMUNOGLOBULIN CONTAINING AND PROLINE RICH RECEPTOR-1 (IGPR-1) | TRUSTEES OF BOSTON UNIVERSITY (US) | 2013-01-03 | — | — | WO | disclosed |
| US-20120322864-A1 | SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC, MODIFIED RNAS AND USES THEREOF | IMMUNE DISEASE INSTITUTE, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322865-A1 | SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC, MODIFIED RNAS AND USES THEREOF | IMMUNE DISEASE INSTITUTE, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120316220-A1 | METHODS AND COMPOSITIONS FOR TREATING INSECTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| WO-2012145582-A2 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITIONS OF EGFR BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2012-10-26 | — | — | WO | disclosed |
| EP-2513334-A1 | DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | Dicerna Pharmaceuticals, Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120263738-A1 | MULTIPLEX DICER SUBSTRATE RNA INTERFERENCE MOLECULES HAVING JOINING SEQUENCES | DICERNA PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| WO-2012138453-A1 | EFFICIENT PROTEIN EXPRESSION IN VIVO USING MODIFIED RNA (MOD-RNA) | THE GENERAL HOSPITAL CORPORATION (US) | 2012-10-11 | — | — | WO | disclosed |
| EP-2487241-A1 | RNAi agents and compositions useful as carp therapeutics | Westfälische Wilhelms-Universität Münster (DE) | 2012-08-15 | — | — | EP | disclosed |
| WO-2012100172-A2 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF HIF-1A BY DOUBLE STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2012-07-26 | — | — | WO | disclosed |
| US-8227188-B2 | Enhancement of influenza gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| WO-2012082821-A2 | MELANOMA TREATMENTS | MEDIMMUNE, LLC (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20120157511-A1 | 5' PHOSPHATE MIMICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012078637-A2 | COMPOSITION AND METHOD FOR OLIGONUCLEOTIDE DELIVERY | IMMUNE DISEASE INSTITUTE, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142101-A1 | OLIGONUCLEOTIDE END CAPS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| EP-2451823-A2 | COMPOSITIONS AND METHODS FOR ENHANCING PRODUCTION OF A BIOLOGICAL PRODUCT | Alnylam Pharmaceuticals, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| EP-2451940-A1 | BIOPROCESSING | Alnylam Pharmaceuticals, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| EP-2451476-A1 | CELL-BASED BIOPROCESSING | Alnylam Pharmaceuticals, Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| US-8168606-B2 | RNAi inhibition of alpha-ENaC expression | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20120095200-A1 | COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY NUCLEIC ACID CONTAINING A DICER SUBSTRATE AND A RECEPTOR BINDING REGION | DICERNA PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| EP-2437751-A2 | PEPTIDE DICER SUBSTRATE AGENTS AND METHODS FOR THEIR SPECIFIC INHIBITION OF GENE EXPRESSION | Dicerna Pharmaceuticals, Inc. (US) | 2012-04-11 | — | — | EP | disclosed |
| EP-2437752-A2 | PEPTIDE DICER SUBSTRATE AGENTS AND METHODS FOR THEIR SPECIFIC INHIBITION OF GENE EXPRESSION | Dicerna Pharmaceuticals, Inc. (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120046346-A1 | SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC, MODIFIED RNAS AND USES THEREOF | IMMUNE DISEASE INSTITUTE, INC. (US) | 2012-02-23 | — | — | US | disclosed |
| US-8119612-B2 | RNAi inhibition of alpha-ENaC expression | NOVARTIS AG (CH) | 2012-02-21 | — | — | US | disclosed |
| EP-2418707-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT AND MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT | Idemitsu Kosan Co., Ltd. (JP) | 2012-02-15 | — | — | EP | disclosed |
| EP-2414374-A2 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF KRAS BY ASYMMETRIC DOUBLE-STRANDED RNA | Dicerna Pharmaceuticals, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| WO-2012006243-A2 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF BETA-CATENIN BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006241-A2 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF ANDROGEN RECEPTOR BY DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
| EP-2403863-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | Alnylam Pharmaceuticals Inc. (US) | 2012-01-11 | — | — | EP | disclosed |
| WO-2011163121-A1 | MULTIFUNCTIONAL COPOLYMERS FOR NUCLEIC ACID DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | WO | disclosed |
| US-20110287038-A1 | METHOD FOR TREATING SOLID TUMORS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2011-11-24 | — | — | US | disclosed |
| WO-2011146862-A1 | METHODS FOR INDUCING SELECTIVE APOPTOSIS | BELLICUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| US-20110288147-A1 | Compositions and methods for the specific inhibition of gene expression by DSRNA containing a tetraloop | DICERNA PHARMACEUTICALS, INC. | 2011-11-24 | — | — | US | disclosed |
| US-20110286980-A1 | METHODS FOR INDUCING SELECTIVE APOPTOSIS | BAYLOR COLLEGE OF MEDICINE | 2011-11-24 | — | — | US | disclosed |
| WO-2011140182-A2 | OPTIMIZED DEGENERATIVE MUSCLE DISEASE DIAGNOSTICS AND TREATMENTS | MEDIMMUNE, LLC (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011133871-A2 | 5'-END DERIVATIVES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133868-A2 | CONFORMATIONALLY RESTRICTED DINUCLEOTIDE MONOMERS AND OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133876-A2 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
| EP-2379083-A2 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | Dicerna Pharmaceuticals, Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2011130624-A2 | SUSTAINED POLYPEPTIDE EXPRESSION FROM SYNTHETIC, MODIFIED RNAS AND USES THEREOF | IMMUNE DISEASE INSTITUTE, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130566-A2 | METHOD FOR TREATING SOLID TUMORS | BELLICUM PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011123621-A2 | 2' AND 5' MODIFIED MONOMERS AND OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011119901-A1 | GENE AMPLIFICATION AND TRANSFECTION METHODS AND REAGENTS RELATED THERETO | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20110223665-A1 | ENHANCEMENT OF siRNA SILENCING ACTIVITY USING UNIVERSAL BASES OR MISMATCHES IN THE SENSE STRAND | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| WO-2011109600-A1 | COMPOSITIONS AND METHODS FOR MODIFYING THE GLYCOSYLATION PATTERN OF A POLYPEPTIDE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011109294-A1 | LIPID DELIVERY FORMULATIONS | DICERNA PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011109427-A2 | IMPROVING THE BIOLOGICAL ACTIVITY OF SIRNA THROUGH MODULATION OF ITS THERMODYNAMIC PROFILE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011103137-A1 | CELL-BASED METHODS AND REAGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011005861-A9 | OLIGONUCLEOTIDE END CAPS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011094580-A2 | CHELATED COPPER FOR USE IN THE PREPARATION OF CONJUGATED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | WO | disclosed |
| EP-2348017-A1 | AROMATIC AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | Mitsui Chemicals, Inc. (JP) | 2011-07-27 | — | — | EP | disclosed |
| EP-2341943-A2 | COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DSRNA POSSESSING MODIFICATIONS | Dicerna Pharmaceuticals, Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| EP-2338186-A1 | ORGANIC LIGHT EMITTING DEVICE AND MATERIALS FOR USE IN SAME | Universal Display Corporation (US) | 2011-06-29 | — | — | EP | disclosed |
| WO-2011075188-A1 | DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | DICERNA PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | WO | disclosed |
| US-20110150894-A1 | METHODS OF MODULATING ANGIOGENESIS VIA TRPV4 | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2011-06-23 | — | — | US | disclosed |
| US-20110135632-A1 | METHODS FOR THE MODULATION OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110130440-A1 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110123520-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| EP-2321414-A1 | ENHANCEMENT OF SIRNA SILENCING ACTIVITY USING UNIVERSAL BASES OR MISMATCHES IN THE SENSE STRAND | Alnylam Pharmaceuticals Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-7943592-B2 | RNAi inhibition of alpha-ENaC expression | NOVARTIS AG (CH) | 2011-05-17 | — | — | US | disclosed |
| US-20110111056-A1 | PEPTIDE DICER SUBSTRATE AGENTS AND METHODS FOR THEIR SPECIFIC INHIBITION OF GENE EXPRESSION | DICERNA PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-7939508-B2 | RNAi inhibition of alpha-ENaC expression | NOVARTIS AG (CH) | 2011-05-10 | — | — | US | disclosed |
| US-20110097707-A1 | RNAi Agents Comprising Universal Nucleobases | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| EP-2295421-A1 | AROMATIC AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | Idemitsu Kosan Co., Ltd. (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-20110059187-A1 | PEPTIDE DICER SUBSTRATE AGENTS AND METHODS FOR THEIR SPECIFIC INHIBITION OF GENE EXPRESSION | DICERNA PHARMACEUTICALS, INC. (US) | 2011-03-10 | — | — | US | disclosed |
| US-7893224-B2 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20110033859-A1 | RNAi INHIBITION OF INFLUENZA VIRUS REPLICATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| WO-2011017137-A2 | METHODS AND COMPOSITIONS FOR TREATING INSECTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| WO-2011013859-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE | FUJIFILM CORPORATION (JP) | 2011-02-03 | — | — | WO | disclosed |
| WO-2011013843-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE | FUJIFILM CORPORATION (JP) | 2011-02-03 | — | — | WO | disclosed |
| US-20110021604-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF KRAS BY ASYMMETRIC DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2274425-A2 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | Alnylam Pharmaceuticals Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2011005765-A1 | BIOPROCESSING | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011005786-A2 | COMPOSITIONS AND METHODS FOR ENHANCING PRODUCTION OF A BIOLOGICAL PRODUCT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011005861-A1 | OLIGONUCLEOTIDE END CAPS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011005860-A2 | 5' PHOSPHATE MIMICS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011005793-A1 | CELL-BASED BIOPROCESSING | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-20110003881-A1 | SINGLE STRANDED EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | DICERNA PHARMACEUTICALS, INC. | 2011-01-06 | — | — | US | disclosed |
| US-20100331389-A1 | Compositions and methods for the specific inhibition of gene expression by dsRNA containing modified nucleotides | DICERNA PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2010141724-A2 | PEPTIDE DICER SUBSTRATE AGENTS AND METHODS FOR THEIR SPECIFIC INHIBITION OF GENE EXPRESSION | DICERNA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141726-A2 | PEPTIDE DICER SUBSTRATE AGENTS AND METHODS FOR THEIR SPECIFIC INHIBITION OF GENE EXPRESSION | DICERNA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010115202-A2 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF KRAS BY BLUNT ENDED DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| WO-2010115206-A2 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF KRAS BY ASYMMETRIC DOUBLE-STRANDED RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20100249214-A1 | MULTIPLEX DICER SUBSTRATE RNA INTERFERENCE MOLECULES HAVING JOINING SEQUENCES | Dicerna Pharmaceuticals | 2010-09-30 | — | — | US | disclosed |
| WO-2010101951-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-09-10 | — | — | WO | disclosed |
| EP-2224005-A1 | RNAi inhibition of alpha-ENaC expression | Novartis AG (CH) | 2010-09-01 | — | — | EP | disclosed |
| EP-2223693-A1 | RNAi inhibition of alpha-ENaC expression | Novartis AG (CH) | 2010-09-01 | — | — | EP | disclosed |
| EP-2223692-A1 | RNAi inhibition of alpha-ENaC expression | Novartis AG (CH) | 2010-09-01 | — | — | EP | disclosed |
| EP-2223695-A1 | RNAi inhibition of alpha-ENaC expression | Novartis AG (CH) | 2010-09-01 | — | — | EP | disclosed |
| EP-2223694-A1 | RNAi inhibition of alpha-ENaC expression | Novartis AG (CH) | 2010-09-01 | — | — | EP | disclosed |
| EP-2224004-A1 | RNAi inhibition of alpha-ENaC expression | Novartis AG (CH) | 2010-09-01 | — | — | EP | disclosed |
| US-20100216971-A1 | RNAi Inhibition of Alpha-ENaC Expression | NOVARTIS AG | 2010-08-26 | — | — | US | disclosed |
| US-20100216972-A1 | RNAi Inhibition of Alpha-ENaC Expression | NOVARTIS AG | 2010-08-26 | — | — | US | disclosed |
| US-20100210513-A1 | RNAi Inhibition of Alpha-ENaC Expression | NOVARTIS AG | 2010-08-19 | — | — | US | disclosed |
| US-20100210514-A1 | RNAi Inhibition of Alpha-ENaC Expression | NOVARTIS AG | 2010-08-19 | — | — | US | disclosed |
| US-7772387-B2 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100190714-A1 | RNAi Inhibition of Alpha-ENaC Expression | NOVATIS AG | 2010-07-29 | — | — | US | disclosed |
| US-20100184841-A1 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | DICERNA PHARMACEUTICALS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010080129-A2 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | DICERNA PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20100173974-A1 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | DICERNA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100173973-A1 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | DICERNA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| EP-2202239-A1 | RNAI inhibition of influenza virus replication | Alnylam Pharmaceuticals Inc. (US) | 2010-06-30 | — | — | EP | disclosed |
| US-7718632-B2 | RNAi inhibition of alpha-ENaC expression | NOVARTIS AG (CH) | 2010-05-18 | — | — | US | disclosed |
| WO-2010047707-A1 | ORGANIC LIGHT EMITTING DEVICE AND MATERIALS FOR USE IN SAME | UNIVERSAL DISPLAY CORPORATION (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2009155504-A9 | METHODS FOR THE MODULATION OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
| EP-2171059-A2 | RNAI INHIBITION OF ALPHA-ENAC EXPRESSION | Novartis Ag (CH) | 2010-04-07 | — | — | EP | disclosed |
| WO-2010033225-A2 | COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DSRNA POSSESSING MODIFICATIONS | DICERNA PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010011895-A1 | ENHANCEMENT OF SIRNA SILENCING ACTIVITY USING UNIVERSAL BASES OR MISMATCHES IN THE SENSE STRAND | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009155504-A2 | METHODS FOR THE MODULATION OF ANGIOGENESIS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20090312531-A1 | OLIGNUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-7632932-B2 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-12-15 | — | — | US | disclosed |
| WO-2009149239-A1 | METHODS OF MODULATING ANGIOGENESIS VIA TRPV4 | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-12-10 | — | — | WO | disclosed |
| US-20090281298-A1 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| WO-2009126933-A2 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009120878-A2 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| US-7579451-B2 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090156529-A1 | RNAi Inhibition of Alpha-ENaC Expression | NOVARTIS AG | 2009-06-18 | — | — | US | disclosed |
| US-7521454-B2 | Adenine derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| WO-2009020771-A2 | RNAI AGENTS COMPRISING UNIVERSAL NUCLEOBASES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008152131-A2 | RNAI INHIBITION OF ALPHA-ENAC EXPRESSION | NOVARTIS AG (CH) | 2008-12-18 | — | — | WO | disclosed |
| US-20080213891-A1 | RNAi Agents Comprising Universal Nucleobases | ALNYLAM PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| EP-1386923-B1 | NOVEL ADENINE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| EP-1951737-A2 | RNAI INHIBITION OF INFLUENZA VIRUS REPLICATION | Alnylam Pharmaceuticals Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1913011-A2 | OLIGONUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | Alnylam Pharmaceuticals Inc. (US) | 2008-04-23 | — | — | EP | disclosed |
| EP-1834956-A1 | METAL COMPLEX COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2007-09-19 | — | — | EP | disclosed |
| EP-1828215-A2 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | Alnylam Pharmaceuticals Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20070197460-A1 | RNAI INHIBITION OF INFLUENZA VIRUS REPLICATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070188084-A1 | Organic electroluminescence element and display | IDEMITSU KOSAN CO., LTD (JP) | 2007-08-16 | — | — | US | disclosed |
| US-7238812-B2 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | MEJI SEIKA KAISHA, LTD. (JP) | 2007-07-03 | — | — | US | disclosed |
| WO-2007053696-A2 | RNAI INHIBITION OF INFLUENZA VIRUS REPLICATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7157465-B2 | Adenine derivatives | DAINIPPON SIMITOMO PHARMA CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| WO-2006112872-A2 | OLIGONUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006093526-A2 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060074074-A1 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2006-04-06 | — | — | US | disclosed |
| US-7022860-B2 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | MEIJI SEIKA KAISHA, LTD. (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20060035254-A1 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| US-20040132748-A1 | Novel adenne derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1386923-A1 | NOVEL ADENINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
| EP-1026167-B1 | TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND ANTIALLERGIC AGENTS | MEIJI SEIKA KAISHA (JP) | 2003-03-05 | — | — | EP | disclosed |
| US-20020137739-A1 | Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2002-09-26 | — | — | US | disclosed |
| US-6372735-B1 | ANTIHISTAMINES | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-04-16 | — | — | US | disclosed |
| EP-0686636-B1 | TRICYCLIC BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES | MEIJI SEIKA CO (JP) | 2001-04-04 | — | — | EP | disclosed |
| EP-1026167-A1 | TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND ANTIALLERGIC | MEIJI SEIKA KAISHA LTD. (JP) | 2000-08-09 | — | — | EP | disclosed |
| US-6093714-A | AN ANTIALLERGENS FOR TREATMENT AND PREVENTION OF BRONCHIAL ASTHMA, ECZEMA, HIVES, ALLERGIC GASTROINTESTINAL TROUBLES, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS | MEIJI SEIKA KAISHA, LTD. (JP) | 2000-07-25 | — | — | US | disclosed |
| US-5840895-A | INTERMEDIATES FOR ANTIALLERGENS | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1998-11-24 | — | — | US | disclosed |
| EP-0834512-A1 | TRICYCLIC BENZAZEPINE COMPOUNDS | MEIJI SEIKA KAISHA LTD. (JP) | 1998-04-08 | — | — | EP | disclosed |
| US-5686442-A | ANTIALLERGENS | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1997-11-11 | — | — | US | disclosed |
| EP-0686636-A1 | TRICYCLIC BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1995-12-13 | — | — | EP | disclosed |
| EP-0686636-A1 | TRICYCLIC BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1995-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204152-A1 | CHIMERIC POLYNUCLEOTIDES | NSUN3, TRDMT1, NSUN2 | CYP1A2 4683/4885CYP2A6 4399/4885ALDH1A1 3628/4885 |
| US-20200031862-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | ADAR, NCL, SSU72 | CYP1A2 4778/4885CYP2A6 4275/4885ALDH1A1 3796/4885 |
| US-10913767-B2 | Oligonucleotides comprising acyclic and abasic nucleosides and analogs | NSUN2, BCDIN3D, ADAR | CYP1A2 4712/4885CYP2A6 4633/4885ALDH1A1 3836/4885 |
| US-20200354429-A1 | POLYNUCLEOTIDES ENCODING RELAXIN | RXFP1, RXFP2, RXFP4 | CYP1A2 3537/4885CYP2A6 3345/4885ALDH1A1 3793/4885 |
| US-20150133521-A1 | INHIBITORS OF MICRORNAs THAT REGULATE PRODUCTION OF ATRIAL NATRIURETIC PEPTIDE (ANP) AS THERAPEUTICS AND USES THEREOF | NPPA, NPR1, NPR3 | CYP1A2 2867/4885CYP2A6 3291/4885ALDH1A1 3699/4885 |
| US-20200282046-A1 | BETACORONAVIRUS MRNA VACCINE | RNGTT, RNMT, NSUN3 | CYP1A2 3163/4885CYP2A6 2365/4885ALDH1A1 4682/4885 |
| US-20190002890-A1 | POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE | GBA1, GAA, GLA | CYP1A2 3900/4885CYP2A6 3139/4885ALDH1A1 2985/4885 |
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | NSUN2, RNMT, NSUN3 | CYP1A2 4374/4885CYP2A6 3966/4885ALDH1A1 1390/4885 |
| US-10385337-B2 | Oligonucleotide end caps | RNGTT, POLRMT, POLM | CYP1A2 4871/4885CYP2A6 4213/4885ALDH1A1 4045/4885 |
| US-20220096626-A1 | HUMAN CYTOMEGALOVIRUS VACCINE | NSUN2, NSUN3, RNMT | CYP1A2 4856/4885CYP2A6 4582/4885ALDH1A1 4680/4885 |
| US-20190314493-A1 | HUMAN CYTOMEGALOVIRUS VACCINE | NSUN2, NSUN3, RNMT | CYP1A2 4856/4885CYP2A6 4582/4885ALDH1A1 4680/4885 |
| US-20080213891-A1 | RNAi Agents Comprising Universal Nucleobases | NOP2, NOP58, FBL | CYP1A2 4257/4885CYP2A6 4064/4885ALDH1A1 1539/4885 |
| US-10702600-B1 | Betacoronavirus mRNA vaccine | RNGTT, RNMT, NSUN3 | CYP1A2 3163/4885CYP2A6 2365/4885ALDH1A1 4682/4885 |
| US-20170340725-A1 | COMBINATION PIV3/HMPV RNA VACCINES | RBM3, NSUN3, ELAVL3 | CYP1A2 4882/4885CYP2A6 4813/4885ALDH1A1 4880/4885 |
| US-11872278-B2 | Combination HMPV/RSV RNA vaccines | SARNP, RBM3, SYNCRIP | CYP1A2 4829/4885CYP2A6 4651/4885ALDH1A1 4807/4885 |
| US-20190321464-A1 | HUMAN CYTOMEGALOVIRUS RNA VACCINES | NSUN2, NSUN3, SNRPA | CYP1A2 4868/4885CYP2A6 4717/4885ALDH1A1 4549/4885 |
| US-20100184841-A1 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | RNASE1, AGO2, DCLRE1B | CYP1A2 4422/4885CYP2A6 3544/4885ALDH1A1 2370/4885 |
| US-20190015501-A1 | NUCLEIC ACID VACCINES | NSUN3, NSUN2, RNGTT | CYP1A2 4850/4885CYP2A6 4707/4885ALDH1A1 4743/4885 |
| US-20200289639-A1 | CHIKUNGUNYA VIRUS RNA VACCINES | CHIA, EIF2AK2, NSUN3 | CYP1A2 4361/4885CYP2A6 3893/4885ALDH1A1 3760/4885 |
| US-20200318118-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF KRAS BY ASYMMETRIC DOUBLE-STRANDED RNA | KRAS, AGO2, RNASE1 | CYP1A2 4837/4885CYP2A6 4620/4885ALDH1A1 4161/4885 |
| US-20180296662-A1 | SEXUALLY TRANSMITTED DISEASE VACCINES | DIS3, KLK3, RTCB | CYP1A2 4274/4885CYP2A6 3397/4885ALDH1A1 3414/4885 |
| US-20200129608-A1 | RESPIRATORY SYNCYTIAL VIRUS VACCINE | SYNCRIP, SRRT, SARNP | CYP1A2 4767/4885CYP2A6 4389/4885ALDH1A1 4741/4885 |
| US-20240209068-A1 | MUCOSAL EXPRESSION OF ANTIBODY STRUCTURES AND ISOTYPES BY MRNA | NSUN3, IGLV6-57, MRPS23 | CYP1A2 4653/4885CYP2A6 2924/4885ALDH1A1 4491/4885 |
| US-11344504-B1 | Combinations of mRNAs encoding immune modulating polypeptides and uses thereof | IL36G, IL23R, CD74 | CYP1A2 4884/4885CYP2A6 4712/4885ALDH1A1 4745/4885 |
| US-20130123342-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF KRAS BY ASYMMETRIC DOUBLE-STRANDED RNA | KRAS, AGO2, RNASE1 | CYP1A2 4837/4885CYP2A6 4620/4885ALDH1A1 4161/4885 |
| US-20220211743-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | SLC2A8, IGF2BP2, SLC2A2 | CYP1A2 4205/4885CYP2A6 3441/4885ALDH1A1 2503/4885 |
| US-20190144859-A1 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF TRANSTHYRETIN (TTR) BY DOUBLE-STRANDED RNA | TTR, SARNP, RNASE1 | CYP1A2 4665/4885CYP2A6 4411/4885ALDH1A1 4550/4885 |
| US-10428106-B2 | Phosphate replacement mRNA cap analogs | RNGTT, RNMT, CPSF6 | CYP1A2 4857/4885CYP2A6 3919/4885ALDH1A1 4428/4885 |
| US-11045540-B2 | Varicella zoster virus (VZV) vaccine | IRF3, RNMT, VAC14 | CYP1A2 4870/4885CYP2A6 4689/4885ALDH1A1 4859/4885 |
| US-20110097707-A1 | RNAi Agents Comprising Universal Nucleobases | NOP2, NOP58, FBL | CYP1A2 4257/4885CYP2A6 4064/4885ALDH1A1 1539/4885 |
| US-20180318409-A1 | CANCER VACCINES | TP53, RNMT, RBM3 | CYP1A2 4875/4885CYP2A6 4783/4885ALDH1A1 4358/4885 |
| US-20240100169-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | PCSK9, LDLR, PCSK7 | CYP1A2 4822/4885CYP2A6 4579/4885ALDH1A1 4609/4885 |
| US-20190117798-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS | HDLBP, APOB, TSG101 | CYP1A2 4865/4885CYP2A6 4541/4885ALDH1A1 3952/4885 |
| US-10689647-B2 | Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA | SERPINC1, NSUN3, AGO2 | CYP1A2 4747/4885CYP2A6 4640/4885ALDH1A1 4498/4885 |
| US-20070197460-A1 | RNAI INHIBITION OF INFLUENZA VIRUS REPLICATION | SNRPE, EIF2AK2, AGO2 | CYP1A2 4676/4885CYP2A6 4002/4885ALDH1A1 4078/4885 |
| US-20240110214-A1 | RNA MANUFACTURING | ADAR, UPF1, NSUN3 | CYP1A2 4098/4885CYP2A6 4347/4885ALDH1A1 3591/4885 |
| US-10407683-B2 | Circular polynucleotides | POLN, POLRMT, POLI | CYP1A2 4795/4885CYP2A6 4717/4885ALDH1A1 4465/4885 |
| US-20230029227-A1 | TUNABLE REVERSIR TM COMPOUNDS | MTREX, SNRPE, LDLR | CYP1A2 4315/4885CYP2A6 3059/4885ALDH1A1 3767/4885 |
| US-20200254086-A1 | EFFICACIOUS MRNA VACCINES | CD4, CD14, CD69 | CYP1A2 3914/4885CYP2A6 4104/4885ALDH1A1 4486/4885 |
| US-20180291400-A1 | METHODS AND COMPOSITIONS TO INCREASE HUMAN SOMATIC CELL NUCLEAR TRANSFER (SCNT) EFFICIENCY BY REMOVING HISTONE H3-LYSINE TRIMETHYLATION, AND DERIVATION OF HUMAN NT-ESC | SUV39H1, SUV39H2, EHMT1 | CYP1A2 4429/4885CYP2A6 4581/4885ALDH1A1 4023/4885 |
| US-20180273977-A1 | MULTIMERIC MRNA | NSUN3, METTL16, RNMT | CYP1A2 4858/4885CYP2A6 4760/4885ALDH1A1 3490/4885 |
| US-20200113844-A1 | COMBINATIONS OF MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | IL36G, IL23R, CD74 | CYP1A2 4884/4885CYP2A6 4712/4885ALDH1A1 4745/4885 |
| US-10426738-B2 | Polynucleotides encoding methylmalonyl-CoA mutase | POLM, EMG1, MCM6 | CYP1A2 4660/4885CYP2A6 3554/4885ALDH1A1 3153/4885 |
| US-20230364083-A1 | HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA | HDAC5, HDAC6, HDAC9 | CYP1A2 4467/4885CYP2A6 2977/4885ALDH1A1 1018/4885 |
| US-11667918-B2 | Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA | SERPINC1, NSUN3, AGO2 | CYP1A2 4747/4885CYP2A6 4640/4885ALDH1A1 4498/4885 |
| US-10150965-B2 | Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA | TTR, RNASE1, SARNP | CYP1A2 4706/4885CYP2A6 4470/4885ALDH1A1 4305/4885 |
| US-20120157511-A1 | 5' PHOSPHATE MIMICS | NSUN2, RNGTT, RNMT | CYP1A2 4498/4885CYP2A6 3789/4885ALDH1A1 3422/4885 |
| US-20230390379-A1 | RESPIRATORY SYNCYTIAL VIRUS VACCINE | SYNCRIP, SRRT, SARNP | CYP1A2 4767/4885CYP2A6 4389/4885ALDH1A1 4741/4885 |
| US-20160331828-A1 | NUCLEIC ACID VACCINES | NSUN3, NSUN2, RNGTT | CYP1A2 4850/4885CYP2A6 4707/4885ALDH1A1 4743/4885 |
| US-20130130378-A1 | OLIGONUCLEOTIDES COMPRISING ACYCLIC AND ABASIC NUCLEOSIDES AND ANALOGS | ADAR, TYMS, POLM | CYP1A2 3009/4885CYP2A6 2355/4885ALDH1A1 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.